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ABSTRACT
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Near the turn of the 20th century scientist were beginning to discover compounds that
were essential for humans beyond the previous establish, protein, grains, and fat 1. This ushered
in a new field of studying a class of molecules that were considered “vital amines” later shortened
to vitamins2. Vitamin D was the fourth of this new class of compound that was identified and
over the next decades was shown to play a vital role in the homeostasis of calcium and
phosphorous3, 4. The dominant active form of vitamin D is formed within the body through a
series of oxidation reactions acting upon its dietary source vitamin D2 or UV light activated
precursor 7-dehydrocloesteroil leading to the main active form 1,25(OH)2 D3, calcitriol5-7. In the
1980s exploration into the activity of other vitamin D metabolites was conducted by Esvelt and
it was found that the final metabolic product of the activated pathway for vitamin D, calcitroic
acid, had activity in complex formation with the vitamin D receptor (VDR)8. Our work focuses on
the implementation of new methods of separation and measurement that were not available at
the time of that study to explore the endogenous localization and concentration of calcitroic acid.

ii

This work utilizes the methods of liquid chromatographic separation with tandem mass
spectrometric detection9. An analytical method was optimized based on the ionization and
fragmentation of calcitroic acid for the detection in in vitro and in vivo studies. This method was
pair with a reverse phase ultra-high performance liquid chromatographic separation (UHPLC–
MS/MS).
The metabolic stability of calcitroic acid was explored to determine whether it was a true
end product of the metabolism of vitamin D10. It was found that calcitroic acid was stabile under
enzymatic oxidative conditions. The conjugation of calcitroic acid for excretion and circulation
was explored using in vitro assays.
Separation methods were optimized for sample extraction of calcitroic acid from mouse
tissues. A strong anion exchange (SPE) method was developed for the analysis to allow for
removal of interfering species during in vivo studies. The concentration of native calcitroic acid
was then measured in several different mouse tissues and determined to be below the limit of
detection for the developed method. Alternative forms of selectively during these studies were
explored based on the derivatization of calcitroic acid using dienophile dyes.
To understand the role that the VDR in inflammatory bowel disease (IBD), A outbred
mouse model was optimized for the screening efficacy of compounds, including calcitroic acid 11.
Optimization to the measurements conducted within the study, vehicle and delivering of the
drugs as well as the chemical irritant and sample preparation were optimized for low variance
measurement to be conducted on the reduction of colitis in mice.
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Introduction to Vitamin D

1.1

History of Vitamin D
During the turn of the twentieth century nutritional requirements were still in the very

early stages of development. Von Liebig was the first to suggest that a balance of different
proteins, grains, minerals, and fats were required for physiological homeostasis. Near the turn of
the 20th century, scientists were starting to question the ability to sustain life on the three
macronutrients. Funk first postulated the need of essential dietary requirements called vital
amines with the discovery of vitamin A2. This nomenclature was carried forward for the future
classifications of compounds shortened to vitamins. A sample of cod liver oil that was separated
into a non-aqueous and aqueous portion and were given the names vitamin A and B, respectively.
It was speculated that the disease rickets was caused by a deficiency in vitamin A at the time.
Mellanby was a English chemist who was interested in the treatment of rickets and demonstrated
in a canine model that there was a dietary link to the disease, suggesting vitamin A deficiency 12.
McCollum was skeptical of the finding of Mellanby and looked to find if a different vitamin was
behind the treatment of the disease. McCollum hypothesized that vitamin A was not taking place
in the efficacy of the treatment3. He took a sample of the cod liver oil and bubbled oxygen
through the mixture to deactivate the present Vitamin A. After the oxidation, the effect of the
mixture on the treatment of rickets remained3, 4.
While the field of dietary vitamin D was the first place that it was discovered, the history
behind biologically synthesized vitamin D had a large impact on the treatment of rickets as well
all over the world at the beginning of the 20th century. Huldschinsky and Chick both found a
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correlation with the exposure to ultraviolet light in subject with sufficient fat present in their
diets seemed to treat rickets as well13, 14. Steenbock added to this work exploring rickets within
rats that were exposed to UV light as well as animals that were given food that was exposed the
this light source and found that both proved effective in the prevention of rickets15. He concluded
that some species was being activated within the food source that was leading to the treatment
of the disease. The evidence of 7-dehydrocholesterol as the precursor to vitamin D3 through UV
light activation would not become a validated mechanism until that mid-1970s16, 17.
Scientist concluded the fat-soluble portion of cod liver extract contained some other
essential component and sought to identify the active compound. Askew et al. worked on the
identification and were the first to separate vitamin D 218. Because the moniker of vitamin C was
already assigned to the water soluble species responsible of the treatment of scurvy, the fourth
vitamin was given the title of vitamin D19. A misidentification led to the discarding of the original
vitamin D1 making vitamin D2 the first form to be separated and confirmed.

1.2

Vitamin D Metabolic Pathways
Vitamin D metabolism was overshadowed by other vitamins but over the next decades

vitamin D was found to have an interesting metabolic pathway decades after its initial separation.
Further separation of the aqueous portion demonstrated that vitamin B was a class of
compounds of similar structure with interesting metabolism, which dominated the field vitamin
research for decades1. Once the function of calcium and phosphate homeostasis was determined
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as a function of vitamin D metabolism, the efficacy of the forms of vitamin D were determined20,
21.

In the process the predominant members of the metabolic pathway were determined.
The metabolic pathways of vitamin D undergo two routes dependent upon the activation

of the compound. The distinction between vitamin D2 and D3 effects the initial metabolic pathway
of the material. As shown in Schematic 1, 7-dehydrocholesterol can be converted into
cholecalciferol through exposure to UV light5. Vitamin D2 undergoes a different reaction to
desaturate the 22,23-sidechain paired with the demethylation at the 24-position, producing
Vitamin D3. This reaction is enzymatically done by CYP24A1 leading again to cholecalciferol,
vitamin D36. The activation to the circulating form of vitamin D is then mitigated by another
oxidative P450 enzyme either CYP24A1 or CYP2R17. The product of this metabolism is calcidiol,
or 25-(OH) D3.

Schematic 1 – Metabolic pathways for the cholecalciferol with a representation of conversion into calcidiol for circulation.
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At this point the metabolism branches between an activated form of the vitamin with
high efficacy and an inactive clearance pathway. A representation of the pathway is shown in
Schematic 2. The most biologically active form of vitamin D was found to be calcitriol, which
strongly induces the formation of the vitamin D receptor complex22. This is formed from the
further oxidation of calcidiol by the P450 enzyme CYP27B1 located within renal cells6. Due to the
high activity of calcitriol, it is well regulated. The conversion to a less active metabolite is
necessary to maintain homeostasis within animals. A series of P450 controlled reactions allow
for a series of oxidative reactions that lead to the sidechain shortening of calcitriol through, 24oxo-1,23,25(OH)3D323. This compound is then oxidized to 24,26,26,27-tentranor-1,23(OH)2D3 by
the CYP24A1 enzyme. Finally, the last observed oxidation of vitamin D conducted by CYP24A1
converts the species to the speculated exception product. 1α-hydroxy-23-carboxy-24,25,6,27teranorvitamin D3, referred to as calcitroic acid24.

Schematic 2 – Representation of the oxidative pathway that vitamin D undergoes through the active form calcitriol.

While calcitriol is of interest to study the function of vitamin D, the metabolism is equally
as important for the clearance of vitamin D and identification of possible pathways in maintaining
homeostasis. A representation of the pathway is shown in Schematic 3. Calcidiol alternatively to
taking on the hydroxyl at the α1 position, can begin the chain shortening reaction that calcitriol
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was seen to undergo above. The same enzyme CYP24A1 is responsible for the oxidation reaction
that covert calcidiol into 24-oxo-23,25(OH)2D3 and then to 24,26,26,27-tetranor-23(OH)D325-27.
Finally, the conversion into the less active clearance product, 23-caroxy-24,25,26,27tetranorvitamin D3, or calcioic acid is the current established product for excretion through the
bile duct and in urine28.

Schematic 3 – Metabolic pathway of vitamin D bypassing the active form for clearance.

1.3

Vitamin D Metabolic Activity
Understanding of the activity of vitamin D came first in function then in form. Early work

as described in Section 1.1 focused on the treatment of the disease rickets. Experiments were
performed to understand the nature of the disease with the incubation of bone samples with
blood samples of animals that had been treated with vitamin D 29. It was found that significant
decalcification occurred within the samples suggesting a regulation of circulating and stored
calcium and phosphate levels.
The first crystallization of the vitamin D receptor (VDR), a member of the nuclear
receptor family, allowed for greater understanding of vitamin D activity30. The expression of
this receptor was found to be mainly present within the endocrine system and well as the
5

intestinal track further adding to the understanding of the calcium homeostasis being a
negative feedback loop where the intestinal absorption of calcium was regulated by this new
nuclear receptor. As previously mentioned, calcitriol was identified as the dominant ligand for
this receptor showing the greatest complex formation and gene expression31. Vitamin D
analogs act as a ligand with the VDR and recruit retinoid X receptor (RXR) to form a
heterodimer complex32.
Esvelt sought to build upon the roles of the metabolic activity of vitamin D metabolites
and found activity within the final oxidative product, calcitroic acid in the VDR complex formed
during in vitro studies8. Activity of a lower magnitude than calcitriol was observed with
calcitroic acid and calcitroic acid methyl ester. Their work also included the dosing of mice with
calcitroic acid and exploring the distribution of calcitroic acid. At the time of these
measurement, a synthesis route for calcitroic acid had not yet been developed preventing
radiolabeled measurement of the dosed samples. Mass spectrometry liquid chromatography
was far away from the modern methods developed around these methods of measurement.

1.4

Significance of Vitamin D Metabolites
Vitamin D is an essential compound for regular cellular proliferation and homeostasis31.

For this reason, vitamin D is a common dietary supplement in both the forms of vitamin D 2 and
D3. Alternatively, to the dietary source’s vitamin D is metabolized through a light activated
reaction on 7-dehydrocholesterol within the skin. While there are many analogs of vitamin D, the
most common circulating form is 25-(OH)D3, which can be metabolized into the most active form
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1,25-(OH)2D3 binding VDR to form a complex that regulates gene expression. Clearance of 1,25(OH)2D3 occurs through a series of oxidative metabolism reactions mitigated by P450 enzymes.
The previously determined excretion product of this metabolism is calcitroic acid. For this reason,
people are exposed to calcitroic acid daily but the activity, localization, and further metabolism
of endogenous calcitroic acid has not previously been explored.
The hope of this project was to increase the understanding of the biological activity of
calcitroic acid and determine if it plays a role in inflammatory mitigation observed with vitamin
D supplements. In addition, this work was based on the question of whether calcitroic acid is the
true end product of the vitamin D metabolic pathway. The role calcitroic acid adds to the body
of vitamin D pharmacology and provides possible new options for drug design for the treatment
of diseases that are centered around the pathways that it takes place within.

1.5

Conclusion
The study of vitamin D has a long history dating back to the first classification of vital

amines. While at first overlooked during the initial separation and through to be a component
of vitamin A from cod liver oil, vitamin D was later found to play a significant role in regulating
cellular function and calcium and phosphate homeostasis in animal20, 21. The initial finding of
vitamin D were thought to be complete until it was proven that the multiple forms of vitamin D
and the possible metabolic pathway allows for negative feedback regulation of calcium and
phosphate homeostasis. A deeper understanding of vitamin D metabolic regulation grew to the
position where is sits today where many oxidative P450 enzymes that are responsible for its

7

activation, and clearance have been identified. Modern methods have been developed for the
quantification of vitamin D levels within patients allowing for its concentration to be used as a
diagnostic tool in medicine33, 34.
Activity was observed in the form of calcitroic acid, a compound previously considered
to be an end product of the vitamin D metabolic pathway8. The work described within this
dissertation lays out the exploration of the presence of calcitroic acid at concentrations able to
mitigate a biological response. The work set out to build upon the body of vitamin D research in
hopes to identify new mechanisms that could be targeted for drug discovery.
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2

Liquid Chromatographic Mass Spectrometric Measurement of

Calcitroic Acid
2.1

Instrumental Techniques
The analysis of calcitroic acid has previously been conducted through radiolabeling. This

included the administration of radioactively labeled vitamin D3 to rats9. The advantage to a
method such as this includes great sensitivity that is available with the detection of radioactive
species and no background interference from native biological samples. The tradeoff with this
method is its inability to determine the structure of radioactive species. In addition, to this
hindrance, the cost of radiolabeling comes with either labor intensive reactions or the purchasing
of derivatized materials. Due to these limitations the measurement of calcitroic acid through
liquid chromatographic tandem mass spectrometric detection was explored.

2.2.1 Introduction to Mass Analyzer
An Alternative to radiolabeled methods, calcitroic acid can be detected using mass
spectrometric detection. Mass spectrometry is a sensitive analytical method that operates on the
principle of ionization of analytes and then subjecting them to an electromagnetic field. The field
then can separate out these species based on the ratio of their charge to mass. This allows only
specific species to reach an ion detector35. By cycling through different electromagnetic fields in
a series called a scan, the instrument can measure the quantity of that given ion present in a
sample that is injected into the instrument. While the detection of all the ions that are present
within a given sample seems useful, the complexity of a given biological sample most likely will
11

contain multiple compounds that can generate ions of the same mass to charge ratio as the
analyte. Scientists were able to address this issue in part with the development of the tandem
mass spectrometer. In tandem mass spectrometry (MS/MS) the principle of separation of ions
with the assistance of an electric field is applied multiple times for increased selectivity. Ions pass
through a field selecting for a specific charge to mass ratio. These ions are called precursor ions
which are then sent through a collision cell where an inert gas fragment the ions generating
product ions that are unique in mass to charge ratio. Finally, the product ions are passed through
an additional field, which separates these ions based on the mass to charge ratio. If the product
ion’s mass to charge ratio matches the selected value, the ion’s trajectory sends it to collide with
an electron multiplier generating the signal. This process can include a single fragmentation step,
as was used for the studies described throughout this project. Other instruments that are able to
trap ions in an electromagnetic field, such as an ion trap mass spectrometer (MSn), are able to do
multiple instances of fragmentation for further selectivity and structural information36.
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Schematic 4 – Schematic representation of a triple quadrupole mass spectrometer. Often an exterior vacuum is present to
reduce the strain on the interior vacuums shown35.

2.2.2 Introduction to Ionization Source
While the separation of ions within an electromagnetic field is the heart of the mass
spectrometer, first the instrument must convert neutral species into ions for separation. There
are several different methods which are utilized for the generation of ions for the interface of
the instrument. The first method that was developed is electron impact (EI) ionization37. In this
method a “curtain” of electrons is produced between two electrodes and the sample is passed
through. As electrons collide with compounds passed through the electrodes, the compounds
are imparted with a charge38. This interface is a hard ionization source. The reasoning behind this
title is that collision with an electron often will cause fragmentation of the species before it
reaches the electromagnetic field. Therefore, when a scan of the ions that are present in each
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sample is displayed in a spectrum based on mass to charge, the spectrum reflects the fragments
of the initial molecules that were introduced into the ionization source. This can be a benefit in
some situations, as discussed previously with tandem mass spectrometry, but in this case all the
ions that are generated in an instance within the interface are present withing a single mass
spectrum. Another disadvantage to this interface is its inability to ionize large quantities of
material. With the presence of a diluent in large quantities this interface quickly would become
overwhelmed and diminished ionization would occur on the analyte. Due to this limitation the
most optimal species for electron ionization interfaces are highly volatile species that can avoid
the presence of solvents reaching the ionization source. For the first chapter of mass
spectrometry’s history this was a limitation that carried through to all analysis done with this
method. Chemical derivatization was an option to improve ionization for mass spectrometry but
carried with it a reliance on the efficiency of the reaction to the measurement that was collected.
Then a novel concept changed the field bypassing the issue of overwhelming the interface.
Electrospray ionization (ESI) was a method that allowed for the interface of a mass
spectrometer to take liquid samples into a mass analyzer opening new opportunities for sample
analysis. The electrospray ionization interface creates fine charged droplets. The charge is
imparted onto these droplets by passing the liquid samples through a fine charged capillary. A
drying gas is then passed over the stream of droplets as they migrate towards the mass analyzer.
The drying gas removes the solvent from the droplets causing their size to decrease and bring
the imparted charge closer within each droplet. As these charges become closer, there is a point
where the coulombic interactions of the ions exceed the surface tension of the droplet causing it
to dissociate and transfer the charge from the solvent onto the compounds. The point at which
14

the imbalance in these forces causes the surface tension to break is known as the Rayleigh limit.
The remaining solvent is then removed with a skimmer that filters for charged species. Through
this method liquid samples can be directly interfaced with the mass analyzer. This interface in
comparison to electron ionization is a soft ionization method. The ionization of species in the
interface predominantly generates ions resembling the precursor structure of the compounds
introduced to the interface. The most common types of ions that are generated with this type of
ionization are protonated or deprotonated species. If there are small ions such as sodium ions or
ammonium ions, adducts between compounds and these species are also commonly observed.
Like the electrospray ionization interface, atmospheric chemical ionization (APCI) is a
useful method that allows for the interface of liquid samples to a mass analyzer. The method
uses an external electrode called the corona needle that allows for the charge to be transferred
onto the drying gas that then interacts with the compounds introduced to the interface and
transfers that charge. Both methods are best suited for different types of compounds and could
be selected for depending on the analytes of each study. APCI has been well established as an
ideal ionization source for conjugated systems and working with generating negative ions.

2.2.3 Mass Spectrometric Optimizations for Calcitroic Acid Analysis
The initial conditions that were selected for the interfacing of calcitroic acid for the mass
analyzer were atmospheric pressure chemical ionization based on its structure but with poor
ionization observed, further optimization of the interface was required. Calcitroic acid has both
a conjugated system that runs a portion of the opened ring structure as well as a carboxylic acid
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functionally. These two predominant features were considered when selecting the initial
conditions for measurement of calcitroic acid. Through the incorporation of a buffer into diluent
and mobile phase, the pH of the matrix was adjusted to be higher than the pKa of calcitroic acid
shifting that equilibrium in favor of the deprotonated carboxylic acid form. Standard samples
were run on a Shimadzu 8040 triple quadrupole mass spectrometer. A dual source ionization of
atmospheric chemical ionization and electrospray ionization (DUSI) was utilized for the interface
of the instrument. Direct injections with no liquid chromatography and a single quadrupole scan
were conducted to determine the quality of ionization in the interface. It was found that there
was moderate ionization of the analyte but diminishing returns of the fragment product ions that
were generated from the [M-H]- precursor ion. Further optimization on the collision energy was
conducted but only minor improvements on the signal intensity were observed. Under the
current conditions calcitroic acid could be monitored under simplistic matrix conditions with a
strong precursor ion signal but the method was not robust enough to allow for measurements to
be taken on in vivo samples.
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Figure 1 – Mass Spectrum of a 50 µM standard solution of calcitroic acid. The peaks that are labeled are attributed to the analyte
of the study. Ions below 200 m/z remain within this spectrum but were also present within blanks on the sample instrument and
were considered background signal.

Alternatively, positive mode ionization was conducted on the same standard samples
with an adjusted buffer system to explore if protonation of calcitroic acid would provide greater
signal of the daughter ions that would be used to identify and quantify calcitroic acid within
complex matrices. Figure 1 shows a mass spectrum of a high concentration, 50 µM, calcitroic acid
sample collected on the Shimadzu 8040 tandem mass spectrometer. The mobile phase was
methanol with 0.1% formic acid. The instrument was run using DUIS and event speed was set to
7500 scan/sec. The dominant peaks that appear in the spectrum were 339 m/z, 357 m/z, 397 m/z
and were identified as [M - 2H2O + H]+, [M - H2O + H]+, [M + Na]+ respectively. A modest peak was
observed for the protonated form of calcitroic acid, [M+H]+ with 375 m/z. The distinguishing
feature of this peak when compared with the deprotonated form, was the improvement in the
product ions that were generated in the collision cell. The dominant peaks that were observed in
the product ion mass spectrum of standard solutions of calcitroic acid were characterized. Their
speculated structures are shown in Schematic 5. Both the 357.10 m/z and 339.30 m/z represent
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peak that are attributed to the dehydration of the analyte. This type of transition is not ideal for
a “fingerprinting” product ion identification due to its lack of specificity but when combined with
another ion, such as the 121 m/z transition that is more unique to calcitroic acid can be used for
quantification of the analyte. The additional signal that was available through these peaks was
enough for the optimization of a method that allowed for the measurement of calcitroic acid in
vitro during the microsomal stability assays (MSA) Chapter 2, Figure 14. A multiple reaction
monitoring (MRM) method was then developed to allow for measurement of the ions assigned
to calcitroic acid reducing the scan length and allowing for higher resolution.

Schematic 5 – The proposed structures of the transitions of calcitroic acid generated within the collision cell. The ions 339.23 and
121.10 were used as the quantification ion and finger printing ion, respectively.

Once the initial determination of calcitroic acid’s metabolic activity was assayed, the
exploration of the calcitroic acid’s biological distribution led to revisiting the parameters of the
mass spectrometric analysis. The detection limit of the developed method based on the
calibration curve shown in Figure 2B were 6.1 nM. The initial findings of the biological samples
run under the developed method were unable to distinguish blanks from samples where
calcitroic acid was hypothesized to be present. Adjustments were made to improve the lower
18

limit of detection to avoid large quantities of preconcentration of samples before analysis. The
first step taken was to see whether the conditions could be modified to shift the dominant form
to the [M+H]+ ion. It was found that the change of the ionization to solely ESI provided only a
marginal gain in signal, but the change was kept for the remainder of the analysis. Further review
of the mass spectrum shown in Figure 1 showed the option of optimizing a method of one of the
dehydrated forms that was present in a single quadrupole scan. As previously mentioned, ESI is
considered a soft ionization interface. Some fragmentation can occur for molecules that would
lead to ions other than the protonated and deprotonated forms of the analyte. In the case of
calcitroic acid, the fragment ion intensity far surpassed the signal from the protonated form
under the current conditions. A product ion scan was conducted on the single dehydrated form
of calcitroic acid, shown in Figure 2A, and three ions 339.30 m/z, 121.15 m/z, and 157.15 m/z
were optimized for quantification or qualification. The hypothesized structures for each of these
ions are shown in Schematic 6. Two of the previously identified ions for calcitroic acid were
present in this mass spectra.
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Figure 2 – The initial product ion scan for the dehydrated form of calcitroic acid standards is shown in A. after adjustments to the
collision energies, the ion 339 m/z appeared at higher intensity. Overlay of two calibration curves of calcitroic acid based on the
precursor ion for the method are shown in B. The circles represent the dehydrated form and the triangles the protonated form.
The sensitivity as well as the lower limit of detection was greatly improved working with the dehydrated form.
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Schematic 6 – Proposed product ion transitions of the dehydrated form of calcitroic acid. Two of the structures are based on
the speculations made on the {M+H]+ product ions.

Confirmation of the interface generating the dehydrated form of calcitroic acid was done
to prevent the development of a method dependent on the characteristics of a single standard
solution sample. To assure that no sample degradation occurred during the storage of the
calcitroic acid a standard of calcitroic acid prepared from solid stocks was run under the same
conditions. The chromatograms of both standards are shown in Figure 3. We observed that the
stock solution standard previously used had a higher purity than the new sample, but the ions of
interest were intact and had a retention time corresponding to the initial sample. In addition to
this, Figure 4 shows a thin layer chromatogram (TLC) of the two materials run in 1:9 ethyl acetate:
methanol suggesting that no degradation was observed on a large scale in the dissolved stock
solution that was initially used. For both these reasons, the 357 m/z peak concluded to originate
from the starting material and fragmentation was attributed to the ionization source as the
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retention times of the peak assigned to calcitroic acid matched one another.

Figure 3 – Chromatograms of 50 µM standard solutions of calcitroic acid. Sample A was a working stock solution of calcitroic acid
that was used for the initial development of the dehydrated CTA method. Sample B was a crude solid stock that was prepared to
confirm no degradation was behind the ratio of ions observed in the original sample. The chromatogram of the working sample
contains few impurities will maintaining the same retention time of the solid samples predominant peak.

Stock Solution

A

Crude Solid

of CTA

B

Stock of CTA

Figure 4 – TLC plate of standard solutions of calcitroic acid. The left lane was the working stock solution of calcitroic acid used for
the dehydrated calcitroic acid method. The right lane was the crude solid stock calcitroic acid.

2.3.1 Introduction to Liquid Chromatography
While the specificity of the mass spectrometry is impressive in comparison to many forms
of spectroscopy, the true advantage of this method is observed when paired with a separation
method such as chromatography39. Chromatography is a method that has its roots in some of the
22

initial separations conducted by Mikhail Tsvet to separate out chlorophyll from plants in
petroleum ether with sodium carbonate40. The differential migration of species through a media
based on its interactions with a stationary phase of the system allowed of the separations of
materials without the requirement of a volatile mixture, preventing the exposure to high
temperatures, and allowing for novel chemical characteristics to be the differentiating feature 41.
A common theoretic explanation of this method can be seen in the van Deemter model42.
This model uses a carryover from the method of distillation, theoretic plate count, that remains
will the field today. The number of theoretical plates speaks towards the quality of the separation
with high theoretical plate counts representing the better separations of species, leading to
higher resolution in chromatograms. The model is outlined in Equation 1. The A term of the
equation represents the Eddy diffusion coefficient. This value is independent of the flow rate and
reflects inhomogeneous nature of pathlengths for molecules as they move through a column.
Longitudinal diffusion is expressed with the B coefficient of the function. This is a function of
Brownian motion within a liquid or gas sample. As the time that the sample can disperse within
the column increases this term will increase making it inversely proportional to the flow rate of
the mobile phase. Finally, the C term is a partitioning coefficient that describes both the time that
is required for migration of species from the mobile phase into the stationary phase and a second
term C, with describes the resistance to migration from the stationary phase back into the mobile
phase. The sum of each of these terms provides a reflection on theoretical plate height, H. By
taking the length of the column and dividing it by the height of an individual plate the number of
theoretical plates is found. This model represents the fundamental parameters that must be
considered in any chromatographic separation.
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𝐻 =𝐴+

𝐵
+ 𝐶ū
ū

Eq. 1

Schematic 7 – Overlay of the three terms of the van Deemter model. Each curve can be summed to find the optimal conditions
for a chromatographic separation38.

Due to the length of gas chromatographic columns in comparison to liquid
chromatographic columns the number of theoretical plates has consistently surpassed liquid
chromatographic separations. The decrease in the compressibility of mobile phase has not
allowed for the same lengths of columns without generating an undesirable pressure gradient
across the length of the column. This disadvantage prevents the same quality of resolution of be
achieved with liquid chromatographic conditions. Although, working with liquid samples
prevents the requirement for volatile species and can avoid incorporation methods of drying of
the sample before introduction into the detector. For these reasons liquid chromatography was
used for the analysis of calcitroic acid.
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This initial method of passing a non-polar solvent over a polar stationary phase with
unique migration of compounds was set as a precedent of the normal phase. The separation of
non-polar species could be conducted by substituting the stationary phase for a hydrophobic
species and a hydrophilic mobile phase to allow for the separation of more non-polar species is
considered a reverse phase (opposite of normal phase) separation.

2.3.2 Liquid Chromatographic Optimization for Calcitroic Acid Analysis
The protonated form of calcitroic acid is a bulky structure with a seco-steroidal backbone
allowing for the separation under acidic conditions to be conducted using a reverse phase
column. The starting conditions for the separations of calcitroic acid took this into account when
developing the initial separation for standards. The standard of verapamil HCl was used for the
normalization of the ionization of the instrument and INT–777, a synthetic bile acid, was used as
an extraction efficiency internal standard. Figure 5 shows the separation that was achieved once
the mass spectrometric parameters for each of these compounds conducted and a short gradient
used. A Waters 2.5 µm particle 2.1 x 100 mm C18 bridged ethylene hybrid (BEH) column was used
for the separation. Methanol and water were used as the mobile phase with a 0.1% formic acid
buffer. The flow rate was set to 0.600 mL/min and the gradient went from 50% organic to 99%
organic over 4 minutes. The high organic phase was held and then returned to initial mobile
phase composition to maintain column integrity. This method was crude in comparison to the
later developed methods for the liquid chromatography but was able to handle the separation
that was required for the in vitro microsomal stability assays that are described in chapter 4 of
this thesis.

25

While beginning the extraction procedure described in chapter 4, the sample diluent
composition became of interest for this analysis and required optimization for tissue sample
measurements to be made. The initial conditions that were utilized for a strong anion exchange
extraction included a dilution into 5% formic acid. These conditions proved too harsh for the
structure of calcitroic acid, causing degradation to occur and the biproducts produced separate
peak within the chromatograms collected shown in Figure 6. Several different conditions for the
concentration and type of acid were explored to prevent this degradation from occurring in the
sample. By lowering the concentration and changing to the weaker acid of acetic acid, the ratio
of peak area was shifted back to resembling chromatograms previously collected. It was found
that the substitution for 0.1 % acetic acid as a buffer proved best suited for the analysis without
jeopardizing the solid phase extraction efficiency that is explored in Chapter 4. Future extractions
of tissue samples utilized this method to prevent degradation of calcitroic acid before the
chromatographic analysis.
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Figure 5 – Chromatogram of calcitroic acid separated from two internal standards Verapamil and INT–777. This method
demonstrating proper separation. Note the concentration of CTA is quite high in this sample allowing this method only to be used
in samples with high concentrations.

During the procedure development for the extraction of calcitroic acid from biological
matrices, the transition from high performance liquid chromatography to ultra-highperformance liquid chromatography became of interest. Previously the column that was used for
the separations of calcitroic acid from standards was a Restek C18 column with 5 µM particle size
and internal dimensions of 50 x 4.6 mm. By changing this column for a UHPLC column the same
level of separation was achieved while removing time from the method allowing for higher
sample throughput, ideal for future microsomal assays as well as large batches of tissue samples.
The downside to this change was the need to revisit the instrumental standards during the
chromatographic optimization.
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Figure 6 – Comparison of diluent composition on the chromatography of calcitroic acid samples. Chromatogram A, B, C, and D
are diluted in 0.1% acetic acid, 5% acetic acid, 0.5 % acetic acid, and 5 % formic acid, respectively. We observed that as the
concentration and strength of the acid was decreased, the number of peaks that attributed to degradation products decrease.

Verapamil, the initial instrumental standard, was found to have variable retention times
throughout sample batches, making the integration of the peaks in chromatograms unreliable.
Since the instrumental internal standard is one of the more interchangeable portions of the
method, other alternatives were explored. The potential compounds shown in Schematic 8 were
considered. A majority these standards did not have optimal logD values for proper retention by
a reversed phase column. Several other standards had issues with poor ionization within the
interface and antipyrine formed dimer ions posing questions of the signal consistency. Of the
compounds that were screened for mass spectrometry signal and chromatographic retention,
4,5 diphenylimidazole (4,5–DPI) was identified as the best option for the instrumental internal
standard. Once the mass spectrometric method was optimized for this standard,
chromatography with the UHPLC column was conducted. The initial chromatogram is shown in
Figure 7. There was a significant amount of the 4,5–DPI that was not being retained on the
column and coming out in the void peak preventing consistent integration of the retained species
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among samples. The other standards were then run under the same chromatographic conditions
to see if they presented better retention under these conditions. All the instrumental internal
standards showed the same peak splitting effect. Further optimization of the chromatographic
parameters was then made to address the signal splitting.

Schematic 8 – Structures of the screened molecules for instrumental internal standards for the UHPLC–MS/MS method.
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Figure 7 – Initial chromatographic overlay of the instrumental internal standards screened with strong enough ionization for mass
spectrometric optimization. All three of the internal standards had poor retention on the column under the initial conditions and
further optimization was required to improve retention.

Figure 8 – Chromatograms of 1 µM 4,5–DPI standard solutions prepared with different diluent compositions. The diluent
composition has consequences for the extraction procedure that is described in chapter 4.

Through changes made to the chromatographic parameters, an UHPLC method was
developed with appropriate separation of calcitroic acid from the instrumental internal standard.
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First, the starting composition of the mobile phase was adjusted to explore if the hydrophilicity
of the standard was causing the void peak. A comparison between different diluent compositions
affects upon the retention of 4,5–DPI standard solutions shown in Figure 8. Different column
temperatures were also explored to rule out some form of sample degradation occurring on the
column. The area between the peaks remained consistent suggesting that the change in
retention times was chemical. The initial method for the separation included a hold at the initial
mobile phase composition to allow for polar species to be eluted in the void peak to simplify the
collected chromatograms. This hold was removed from the method and the gradient started at
the initial time of the run, unifying the signal of 4,5–DPI in the chromatogram into a single peak.
The final resulting gradient was as follows, the aqueous and organic mobile phases were optima
grade water with 0.1% formic acid and methanol with 0.1% formic acid, respectively. Samples
were prepared through serial dilution in methanol 0.1% acetic acid. The flow rate was set to 0.500
mL/min and the mobile phase composition started at 20% organic (MP B) and increased to 80%
over 2 minutes. The gradient then continued to increase the organic composition to 99% over 1
minute. The high organic composition was then held for 1 minute before returning to 20% organic
and holding for 1 minute. The time of each separation was 5 minutes. The final resulting method
was conducted on a standard sample of calcitroic acid and 4,5–DPI and the resulting
chromatogram is shown in Figure 9. The instrument standards appear as a single peak and
calcitroic acid has a retention time closer to the tail end of the gradient but not retained after the
gradient is complete. The remaining two minutes after the gradient was intended to prevent
buildup of highly hydrophobic matrix species within the column. The final return to 20 % mobile
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phase B allows for the mobile phase composition within the column to match the start of the
gradient on any subsequent runs.

Figure 9– A chromatograph of a standard solution of calcitroic acid and 4,5–DPI using the developed separation. The gradient is
overlayed in light blue in concentration of organic mobile phase as a percentage.

2.4

Conclusion
The measurement of calcitroic acid has been of interest for many decades. At the time of

its initial discovery the goals of the researchers that conducted those studies had very different
questions in mind. The quantification of in vivo calcitroic acid would have been a challenging
prospect before the innovations in mass spectrometry that allowed for the interface of liquid
samples. The lack of nonspecific derivatizing agents to allow for GC–MS or HPLC–UV Vis detection
come with a series of challenges that will be further discussed in chapter 5. Though every method
that was developed for this study was not optimal for all calcitroic acid measurements, the early
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methods were simple allowing for samples with simple matrices to be properly separated. Later
after further consideration of the conditions, further improvements were achieved that allowed
for the decreasing of the lower limit of detection to 6.1 nM. In addition to the improvements to
the mass analysis, the liquid chromatographic separation that was achieved allowed for a high
throughput method for the measurement of calcitroic acid in complex matrices. The separation
was more robust than the initial method and when paired with the extraction procedure
described in chapter 4, certainty on the distribution of calcitroic acid was determined.
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3

Metabolic Stability of Calcitroic Acid
The metabolic conversion of a compound speaks towards its bioavailability and half-life

within an animal. Pharmacokinetic studies can be used for this purpose but are challenging due
to the interplay between absorption and elimination. Alternatively, in vitro metabolic stability
assays can model the metabolic pathway of a compound and allow for information of key
enzymes to be identified43. The liver and kidneys are responsible for the conversion of most
xenobiotics and native ligands into more hydrophilic species and priming molecules for further
conjugation for excretion and circulation. liver, hepatocytes, can be collected, homogenized, and
centrifuged to isolate membrane bound enzymes responsible to metabolism. The corresponding
fraction of the centrifuged samples are called liver microsomes, a fraction containing the highest
concentration of the endoplasmic reticulum44. By incubation of compounds with the appropriate
cofactor, NADPH, the metabolic activity of the oxidative pathway was explored in this study.

3.1

Phase I Metabolism of Calcitroic Acid
The oxidative metabolism is classified as phase I metabolism and encompasses many

known modifications made to compounds that enter the body. The primary class of enzymes that
conduct these modifications are P450 enzymes44. The oxidation of a compound leads to the
improvement in its hydrophilicity allowing for it to be circulated through the bloodstream and
finally excretion from the bile ducts, or kidneys into the bladder. There are many novel ways in
which xenobiotics have been developed to control the release or activity of a compound that
take advantage of this conversion. While P450 enzymes are predominantly expressed within
hepatocytes, these enzymes are also expressed within renal cells.
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Calcitroic acid has long been identified as an end product to the oxidative metabolism of 1,25dihydroxyvitamin D45, 46. This assumption was made based on the absence of other oxidation
products using in vivo and ex vivo studies.
Calcitroic acid was incubated with human and mouse hepatocytes microsomes in two sets
of replicates along with the two precursors to generate NADPH, G6PGH and NADP+ with the
cofactor Glc-PO4. A reduction is done upon the NADP+ converting it to the proper oxidation state
for the assay. The limited stability of the NADPH during storage and even during the enzymatic
reaction prevents oxidative microsomal activity assays over one hour. The microsomal mixtures
were buffered with a 0.5 M phosphate buffer and microsomes were stored at -80 °C before the
study and allowed to come to room temperature 30 min before the study began. The mixtures
were incubated at 37 °C for the course of the study. Calcitroic acid and microsomal mixture were
combined in the absence of NADPH and an aliquot for the zero time point of the study was taken.
Then, the assay was initiated with the introduction of the NAPDH and 50 µL aliquots were
collected in 10 min intervals for 1 hour. Each of these time points was collected and immediately
quenched when added to a 96 well plate containing 100 µL of methanol containing internal
standard verapamil. The quenched samples were stored on ice throughout the assay. The plate
was then transferred, and vacuum filtered to remove precipitated proteins due to the percentage
of methanol. 100 µL of the filtered samples were diluted to 500 µL in methanol and the resulting
samples analyzed through the previously described mass spectrometric analyses for the
microsomal stability assay.
The assay was conducted and analyzed using the method outlined in Chapter 2. The
integration was automated based on the retention time determined for standard samples. The
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339.30 m/z was used for the quantification of calcitroic acid throughout the procedure. This
signal was normalized to a signal that was observed with the instrumental internal standard,
verapamil. Finally, the time points were normalized to the starting concentration of calcitroic acid
in the microsomal mixture and the natural log was taken of these values were plotted in Figure
10 to demonstrate the first order kinetic conversion of the analyte. The assay was replicated to
confirm the results of the assay.

Figure 10 – Oxidative microsomal stability assay of calcitroic acid conducted with both human (triangles) and mouse (squares).
The slope of the natural log of each assay was determined to not significantly deviate from zero suggesting no activity.

It was found that the slope of the linear regression of the nature log of the time points
did not significantly deviate from zero. This suggested that the activity of P450 enzymes on
calcitroic acid was negligible. These findings were further confirmed with a positive control
conducted with a compound JDP–107 under the same conditions which was found to have half–
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life of 135.9 min. These findings confirm the assumption that was previously made, that calcitroic
acid is the phase I metabolic end product of vitamin D through the 25 oxidative pathways.

3.2

Phase II Metabolism of Calcitroic Acid
While phase I metabolism serves as a mechanism for increased solubility to allow for the

transport, change in activity and final excretion of metabolites, phase II metabolism further
increases the solubility of compounds to increase the clearance and prevents passive cellular
membrane transport. Phase II metabolism is a class of enzymatic reactions in which a conjugate
is added onto a molecule to further increase solubility for its excretion through the bile ducts or
in urine through the bladder. The general title for these enzymes is transferase enzymes with
each type of moiety addition having a sub–class title. Transferase enzymes of interest are
localized within hepatic and renal cells. A common property of each of the possible conjugates is
that they increase aqueous solubility of these compounds in. Some of the most abundant forms
of conjugates include glucuronic acid, glucose, sulfate, and amino acid (glycine, and taurine).
Cellular localization of the enzymes responsible for cellular reactions vary depending on the class.
For example, the uridine 5’-diphospho-glucuronic acid transferase (UDPGA) enzymes47 are
present within the endoplasmic reticulum while the sulfotransferase (SULTs) enzymes 48 are
present in the cytosol. This difference needed to be accounted for along with the cofactors of
each reaction when modeling the process in the in vitro assays. The appropriate centrifugal
fraction was utilized to account for the cellular distribution of the enzymes of interest.
Bile acids, a structurally similar class of molecules to calcitroic acid, have been shown to
undergo phase II metabolism in the liver before secretion through the bile ducts49. In addition,
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vitamin D’s predominant circulating form, 25-hydroxy vitamin D or calcifediol, is shown to
undergo sulfate conjugation further suggesting possible conjugation of calcitroic acid50. The goal
of this set of assays was to determine whether similar metabolic processes govern the final
excretion of vitamin D metabolites that undergo the 1,25 metabolic pathways.

3.2.1 Glucuronic Acid Conjugation of Calcitroic Acid
The first group of activities that was assayed was the conjugation of calcitroic acid with
glucuronic acid. This was speculated to be the most likely form of conjugation that would occur
with this analyte. The proposed reaction is shown in Schematic 9 The conditions were modeled
after the phase II microsomal stability assay described in Shimada et al. (1997)51. Later the assay
conditions were adjusted further to account for the weak initial metabolism of calcitroic acid. A
positive assay control was an established compound that our group had previously found to
undergo this form of conjugation.

Schematic 9 – A proposed reaction for the formation of a glucuronic acid conjugate. Other possible sites for this conjugation could
occur on the 3-hydroxyl position as well as the carboxyl.
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The conditions for the assay were as follows. A microsomal mixture was prepared in a 0.5
M concentration of phosphate buffer with a pH of 7.4. 1 mM of MgCl2 was added to the mixture
for a final concentration of 0.1 M. The surfactant alamethicin 52 was added to the mixture to
disturb the endoplasmic reticulum to insure availability of the uridine phosphotransferase in the
solution. D-Saccharic acid 1,4-lactone53 was used as an inhibitor to the reverse reaction to
prevent the loss of any of the conjugate that may have been formed. Calcitroic acid was then
added to the mixture to the final concentration of 10 µM. The cofactor of UPDGA was added to
a final concentration of 5 mM to start the reaction. Six replicates of both human and mouse
microsomes throughout this study were collected. Microsomes came to room temperature for 1
hour before their addition to the reaction vials. A summary of the final reagent concentrations is
shown in Table 1. The reactions were performed for 2 hours with time point aliquots collected
every 10 min. Each aliquot was quenched in a solution of methanol containing the instrumental
internal standard of (4,5–DPI). Samples were then vacuum filtrated and diluted in methanol 5fold. The samples were then placed in the autosampler of the Shimadzu 8040 for HPLC–MS/MS
analysis following the procedure outlined in Chapter 2.
Table 1 – A summary of the reagents and their respective concentrations for the phase II microsomal stability assay of hepatic
glucuronidation.

Reagent
0.5 M PO4 Buffer

Conc

unit
0.1 M

50 mM UDPGA

0.005 M

50 mM D-saccharic acid 1,4-lactone

0.005 M

0.1 M MgCl2

0.001 mM

1 mM Analyte

0.01 mM

5 mg/mL Alamethicin in DMSO

0.0225 mg/mL
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Human Liver S9 (20mg/mL)

0.44 mg/mL

Flurbiprofen, and analog of ibuprofen, was used as a positive control for the assay.
Flurbiprofen has previously been reported to form a glucuronide conjugate54. The final ionization
of flurbiprofen was unpromising for the activity of the enzyme under these conditions.
Alternatively, activity was observed with both the disappearance of the native species and the
formation of the glucuronic acid conjugate of the lead compound of another project of our group,
MIDD0301. A replicate of the assay was conducted and used as a confirmation of the assay
conditions for calcitroic acid. The results are shown in Figure 11. MIDD0301 was found to have a
half–life of 110.7 min under these conditions.
A replicate of the study was conducted with calcitroic acid with the conditions shown
above. The results are shown in Figure 12. Calcitroic acid was found to have a metabolic assay
slope that did not significantly deviate from zero suggesting stability under hepatic phase II
glucuronic acid metabolism. These findings could be further confirmed with synthesis of the
glucuronic acid conjugated form of calcitroic acid, a project that our group is exploring. Using a
standard sample of the glucuronic acid conjugate of calcitroic acid, would allow for the
monitoring of the formation of the conjugate in the assay in addition to the disappearance of
starting material. The necessity of this type of method development appeared minor as the
current finding suggests that calcitroic acid does not undergo glucuronidation. Futher studies into
renal glucuronide metabolism would allow for a greater understanding of this form of
conjugation on calcitroic acid.
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Figure 11 – Glucuronidation metabolic stability assay using human liver microsomes n = 6 for MIDD 0301. The monitoring of the
loss of MIDD 0301 is reflected on the left while the right shows the normalized signal of its glucuronide increasing during the
assay. The half-life was determined to be 110.7 min.

Figure 12 – The metabolic stability assay of calcitroic acid normalized against an instrumental internal standard. The linear
regression of the natural log of the signal did not significantly deviate from zero suggesting no activity. For this reason, no
metabolic values were assigned for this assay.

3.2.1 Sulfate Conjugation of Calcitroic Acid
Other vitamin D metabolites have been shown to undergo sulfate conjugation leading to
the interest in calcitroic acid’s availability for this moiety addition55. The enzymes responsible for
this conjugation are sulfotransferase (SULTs). They use the cofactor 3'-phosphoadenosine-5’phosphosulfate (PAPS) as a source of sulfate to increase the solubility of both endogenous and
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exogenous compounds. The conjugation can occur at similar sites on the analyte’s structure
including hydroxyl, carboxyl, and amine functionalities56. Schematic 10 is a representation of the
proposed reaction. Incubation with calcitroic acid and hepatic and renal cytosol centrifugal
fractions paired with the cofactor, PAPS, still needs to be explored within our group to confirm
the stability of calcitroic acid. Synthesis of the mono- and di- sulfates of calcitroic acid were
prepared for standard solutions for the development of a HPLC–MS/MS analysis. It was found
that the ionization of these compounds was limiting for the development of a method that would
monitor the formation of the metabolite throughout the study.

Schematic 10 – A representation of the conversion of calcitroic acids conjugation with a sulfate. Both hydroxyl groups could
potentially undergo this conjugation as well as the carboxyl moiety.

The disappearance of the calcitroic acid under the assay conditions may prove to be more
reliable for measures conducted with HPLC–MS/MS. Alternatively, GC–MS was successfully
utilized for the characterization of the synthesized sulfate conjugates. With modifications to the
workup procedure for the metabolic stability samples, a method could be developed with this
instrument for measurements. Once the metabolic stability is determined under these
conditions, a more specific identification of enzymes may be available. By incubation with
individual enzymes under the same reaction conditions the metabolic variables of Km and Vmax
will be determined.
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3.2.2 Amino Acid Conjugation of Calcitroic Acid
Like a previously discussed phase II metabolic processes, conjugation with amino acids is
a mechanism that animals utilize to increase solubility of exogenous and endogenous compounds
for circulation and clearance. The amino acid that is commonly utilized by animals to metabolize
compounds is glycine. The other molecule that will be discussed in this section is taurine, a small
sulfonic acid with a terminal amine. Taurine is present in large quantities in bile and is used as a
substrate in the biological synthesis of taurochenodeoxycholic acid57. Due to the localization and
hepatic circulation of calcitroic acid, the possibility of these forms of conjugation were of interest
to this project. A hypothesized reaction of calcitroic acid is shown in Schematic 11.

Schematic 11 – The representation of the proposed reaction of the calcitroic acid conjugate formation with amino acids and
taurine. Unlike the previous conjugation reactions this reaction would be localized to the carboxyl functional group.

The class of enzymes that are expected to be responsible for this form of conjugation are
acyl-CoA synthetase (BACS) and acyl-CoA: amino acid N-acyltransferase (AAT). When provided
with the cofactor, ATP, BACS can conjugate the coenzyme A with an acetyl moiety (in this reaction
attaching calcitroic acid). Then, the BACS substitutes the CoA with the second cofactor, glycine
or taurine, forming the final product and releasing CoA49.
To monitor the second step of this metabolism calcitroic acid will first need to be modified
into a thioester with CoA. This molecule would then allow for the activity and kinetics of the
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amino acid N-acyltransferase to be determined. Alternatively, to the use of human liver
microsomes, purified BACS will be used for this set of assays. Biological pH and temperature will
still be utilized. Currently the synthesis of CoA-calcitroic acid is still in progress and future
members of this project will conduct this assay. If activity is observed in the assay relevant kinetic
values will be determined and assigned. While the dominant location of this form of conjugation
occurs within the liver, renal phase II metabolism and excretion may be a part of the process.
Each assay will be replicated with the corresponding renal fractions and enzymes to speak
towards the total metabolism.
It has been shown that a series of bile acids that underwent phase II metabolism have the
process reversed by bacteria within the intestine49. Our group is interested in determining if a
similar process occurs. If it is found that phase II metabolism occurs upon calcitroic acid future
assays, conjugated calcitroic acid will be incubated with isolated hydrolases from C. welchii. to
monitor the deconjugation.

3.3

Conclusion
Calcitroic acid was initially determined to be the end product of vitamin D within animals.

This conclusion was determined based on a method of radiolabeling and derivatization reaction
GC–MS which would not be able to discern calcitroic acid from other possible metabolites that
may form. In this study we have shown no significant activity of P450 enzymes occurs upon
calcitroic acid. This suggests calcitroic acid is the true final oxidative metabolite of 1,25 dihydroxyvitamin D. It was also found that a glucuronic acid conjugation assay shown to work on a positive
control of MIDD0301 did not show significant conversion of calcitroic acid into a conjugate in
hepatic conditions. Further assays in this study will continue to explore the possibilities of other
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common phase II metabolism in both hepatic and renal conditions to determine if calcitroic acid
truly is the 1,25 dihydroxy-vitamin D final metabolite.
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4

Identification and Quantification of Calcitroic acid in Biological

Settings
4.1

Introduction
The determination of calcitroic acid’s distribution and concentration were of interest to

determine its biological role within humans. Therefore, mice were first explored due to the
availability of tissue samples and the ability to administer mice with samples of calcitroic acid.
The robust method that was designed for the liquid chromatographic separation and mass
spectrometric measurement of calcitroic acid was the starting point of the detection of calcitroic
acid in biological samples. The method was initially designed employed an organic solvent
induced precipitation of large biological molecules followed by filtration and detection. Methods
have been designed with a procedure like this in mind by Reddy et al28. The method described
in Chapter 2 summarizes what was initially used for the mass spectrometric parameters of the
initial findings.
The goal of this research was to determine if calcitroic acid was present in a concentration
that was sufficient to be biologically active. Previous members of our group have reported that
calcitroic acid is able to bind to the vitamin D receptor (VDR) receptor and form the retinoid-X
receptor (RXR) complex. Understanding the localization of calcitroic acid will speak towards its
ability to induce this complex that is responsible for gene transcription.

4.2

The need for Separation Methods Beyond Liquid Chromatography
The initial studies that were conducted were unable to separate calcitroic acid from the

matrix generated by the background in the respective chromatograms. Previous groups had
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reported a simple liquid–liquid extraction for the separation of bile acids from liver and bile
samples for LC–MS analysis58. The analysis began at this point due to the ease of sample
preparation under similar conditions.
Swiss Webster mice were used during this study. Livers were collected during necropsy
and transported to the lab on ice before homogenization with 1.0 g to 1 mL of MeOH. These
homogenates were centrifuged and passed through a 0.2 µm nylon filter to remove remaining
particulates. The procedure for this instrumental analysis is described in chapter 2. In Figure 13
the generated chromatogram is shown along with the corresponding instrumental parameters.
The chromatogram of the sample was more complex than what was initially expected under
these conditions. No peak with corresponding retention time and product ion ratios was
observed in the initial samples collected.

Figure 13 – Initial method to explore the simplest form of sample preparation for chromatographic separation. It was found that
the background signal was too high, and the chromatographic separation did not allow for the quantification of calcitroic acid.
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It was thought that the sample preparation conditions could be improved by the removal
of matrix that may be suppressing the ionization of the analyte. Forms of additional separation
were then explored to try and address these concerns.

4.3

Liquid–Liquid Extraction
The conditions that were used in the beginning of this extraction were closer to an organic

crash than a liquid–liquid extraction. A liquid–liquid extraction was thought of as a possible
method and researched for this application although was not part of the final implemented
method.
Liquid–liquid extraction operates on the principle that two non–miscible phases allow for
the exchange of compounds at the interface of the phases. The root of this type of exchange is
proportional to the amount of surface area that is generated between these phases. The
partitioning between the two phases will operate on a similar equilibrium as what is observed in
the equilibrium term in the van Demeter model 38.
The most common model of a liquid–liquid extraction is a water:hexane model in which
the logD represents the equilibrium of concentration observed between the two phases. Based
on the calculated logD value of calcitroic acid the partitioning into an organic phase would be
minimal in a water non–miscible solvent. For this reason, liquid–liquid extraction was not
optimized for this study. Another barrier for the incorporation of liquid-liquid extractions would
have been the low through put of samples not allowing for this method to be scaled to larger
numbers of samples.
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4.4

Solid Phase Extraction
Solid phase extraction (SPE) was a logical alternative for the extraction procedure to

minimize the quantity of solvents used and maintain a high throughput of samples through the
procedure. Another advantage of solid phase extraction comes from the ability to utilize unique
interactions such as ionic interactions for the extraction of calcitroic acid. Selectivity based on
hydrophobic interactions was already implemented within the chromatographic separation. If a
new property of calcitroic acid was selected for in the extraction, the method could remove many
structurally similar compounds to simplify the final chromatographic separation. The
preconcentration of the samples was also an option that was explored in the extraction
procedure as the final eluent does not need to match the loading volume of the sample placed
on the solid phase cartridge. The decrease in the amount of diluent led to a final increase
concentration of the sample upwards of 8-fold.
Solid phase extraction can be conducted in an on–line or off–line method. While on–line
methods allow for the high throughput of samples, optimization of extraction methods can be
more cumbersome than off–line methods. The general procedure for the solid phase extractions
is outlined in Schematic 12. Each of the following sections will describe the optimization of
solvents used during the extractions and the effects on the homogenization steps, as well as
chromatographic analysis.
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Schematic 12 – A representation of the basic procedure of a solid phase extraction. Solvents would be matched with the type of
analyte and stationary phase for the best performance59.

4.4.1 Reverse Phase Solid Phase Extraction
The initial conditions that were explored for the separation of calcitroic acid from
biological systems were based on reverse phase interactions. The intermolecular forces that
govern the partitioning and adsorption into a solid phase in these methods rely on the van der
Waals interactions, and π–π stacking dependent on the structure of the analyte and stationary
phase. Other interactions that molecules in the solution may outweigh the energy gained from
these interactions preventing them to be held in the stationary phase. This difference in
functional groups allows for selectivity for hydrophobic species preventing many the large charge
species from interfering with the detection. The disadvantage of this method was that no
additional properties of the analyte beyond its hydrophobicity were selected for in this analysis,
so the simplification of the chromatographic separation were not observed.
To determine the parameters of this extraction, pipette tips affixed with a C18 stationary
phase were explored for this portion of the study. The extraction procedure for this part of the
study is shown in Schematic 13. MilliporeSigma ZipTips™ pipette tip cartridges were used for this
study paired with aqueous and MeOH eluents for the wash and elution steps of the procedure.
Standard solutions of calcitroic acid were prepared and used for the determination of the
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extraction efficiency through the procedure. For higher throughput in measurements, a Tecan
plate reader is used for the measurements of the sample extracted with the SPE. First a spectrum
from 200 – 700 nm of the calcitroic acid standard solution was collected and is shown in the
Figure 14. The wavelength of 264 nm was selected and used for spectrometric measurement
throughout the study. The diluent’s absorption was measured in parallel to these samples and
subtracted from the total absorbance to accurately determine the absorption of calcitroic acid at
this wavelength. The pipette cartridges were pretreated with methanol then water before
aspiration of the samples in an aqueous load solution. The loaded cartridges were then washed
with an aqueous solution to remove hydrophilic species from the cartridge. Finally, the cartridges
were treated with 500 µL of MeOH to elute off the sample into a solution for detection. This
method with standards was found to have a high recovery rate of 95% shown in Figure 15. This
was thought to be promising as it would correspond to a low loss of sample through the
extraction allowing for a low limit of detection for the final extraction procedure. In addition to
these finding the low standard deviation on this extraction prevented the introduction of
variance into the extraction procedure maintaining the accuracy of the measurements.
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Schematic 13 – A representation of the reverse phase extraction procedure of calcitroic acid tissue extraction. The solvent
composition of the load solution was adjusted by the evaporation of the samples and reconstitution in the appropriate solvent.

Figure 14 – An absorbance spectrum of calcitroic acid and two separate solvents of the determination of the optimal intensity of
the detection during the extraction optimization. This was paired with a PDA contour and it was determined that accounting for
impurities, 264 nm would be used as the wavelength for detection.
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Figure 15 – The calculated extraction efficiency through the reverse phase extraction and the expected losses at each step of the
procedure. This method had the highest recovery rate of calcitroic acid standards out of any of the explored solid phase
extractions.

The method was then applied to a series of mouse plasma samples and then analyzed by
mass spectrometry for determining the circulating concentration of calcitroic acid. Mice were
provided supplemental vitamin D in their diet. The mass spectrometry analysis was implemented
again to gain the selectivity over other similar species that may still be present after the
extraction. A representative mass chromatogram of mouse plasma spiked with calcitroic acid to
determine the extraction efficiency in this matrix is shown in Figure 16. It was found that while
there was a high recovery of calcitroic acid through the standard solutions, once plasma samples
were used, the recovery through the procedure was minimal. Figure 4 shows a comparison
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between samples of plasma that had a standard of calcitroic acid added before the reverse phase
solid phase extraction compared to after the extraction procedure. Due to the very poor recovery
through the method and the lack of increased specificity that this extraction provided ionexchange solid phase extractions were alternatively explored.

Figure 16 – A comparison of the recovery during a spiked sample of calcitroic acid that had undergone the reverse solid phase
extraction procedure to a sample that underwent the extraction and then was spiked with calcitroic acid at the same
concentration. The observed loss of calcitroic acid was too large to move forward with this method.

4.4.2 Weak anion exchange Solid Phase Extraction
Weak anion exchange solid phase extraction (WAX–SPE) is a subset of solid phase
extraction that uses the ion–ion interactions between components of a sample and a stationary
phase. Weak anion cartridges have pH dependent charged stationary phase that allow for the
adherence of charged species. This adds an additional property to the extraction procedure.
When the pH of the diluent changes the protonation of the stationary phase removes the charge
from the charge allowing the solubilization of the analyte and elution into the final sample.
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Pipette tips with WAX–SPE cartridges were used for high throughput in the samples for
optimization of the method. The spectrometric measurement and background subtraction of the
reversed phase extraction was used for determining the extraction efficiency through the
cartridges. The findings are shown in Figure 17. The extraction efficiency of the method was
significantly lower than what was observed for the reverse phase method. This suggested that
the interaction with the stationary phase was not as strong for calcitroic acid. The poor loading
of the samples onto the cartridges prevented moving forward with tissue samples under these
extraction conditions. While the weak anion exchange was explored for the extraction procedure,
the more promising strong anion exchange was tested for extraction efficiency.

Figure 17 – A comparison of calcitroic acid present in solvents of the weak anion exchange procedure. It was observed that a
majority of the calcitroic acid remained within the initial load solution not properly interacting with the stationary phase.

4.4.3 Strong Anion Exchange Solid Phase Extraction
Strong Anion Exchange Solid Phase Extraction (SAX–SPE) operates similarly to weak anion
exchange reversing the role of weak electrolyte onto the analyte. While this part is shifted the
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use of ion–ion interactions for the adsorption of the charged species from a solution onto a
stationary phase for later elution based on ion displacement remains. The primary difference
between a strong and weak anion exchange method is weak anion exchange works more as a
displacement of ions where the analyte is best suited if it has a permanent charge. The stationary
phase then binds with an energetically more favorable ion displacing the charged analyte into
the solution. In a strong anion exchange, the stationary phase has a permanently positively
charged moiety that is better suited for the pairing of ions that have a pKa that can be used to
change from a charged to neutral state35. Calcitroic acid’s pKa made it well suited for this type of
extraction method.
Phenomenex HyperSep™ SAX Strong Anion Exchanger SPE Cartridges were used for this
solid phase extraction. The cartridges utilized for this analysis were a more traditional tube
cartridge in which solvents would be loaded and eluted in a single direction. These cartridges
reduced the throughput of the method but allowed for the higher accuracy in flow rate over the
cartridges. In future studies, the implementation of a solid phase extraction manifold could
further increase the accuracy of flow rates for the procedure and the parameter could be more
accurately optimized. Another property of these cartridges was the phenyl moiety in the
stationary phase shown in Schematic 14. This functional group allowed for π–π stacking a
hydrophobic effect that increased the selectivity even greater.
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Schematic 14 – A summary highlighting the selectivity gained through a strong anion stationary phase.

The method that was developed for determination of the extraction efficiency of
cartridges for the reverse phase method was once again utilized for the SAX–SPE. Measurements
of standard samples of calcitroic acid that underwent extraction through the SAX–SPE were
measured with the Tecan plate reader. The findings were reported in Figure 18. It was found that
calcitroic acid through the initial procedure exhibited 82% recovery. This was a decrease in the
recovery of the sample suggesting that some of the calcitroic acid remained on the stationary
phase based on the absorbance observed of each solution. While the recovery was lower for this
method when compared to the reverse phase extraction the sample lower standard deviations
were observed once again preventing high variance in the final reported concentrations of
calcitroic acid in the initial samples. The quantity recovered spoke towards a more productive
interaction between calcitroic acid and the stationary phase than what was observed with the
weak anion cartridges. The strong anion exchange for this reason was further explored over the
weak anion exchange for the extraction of calcitroic acid from tissue samples.
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Figure 18 – A comparison of the three different types of solid phase extraction explored within this study. It was found that the
greatest recovery was observed in standard solutions with the C18 stationary phase, but the strong anion exchange method
provided greater amounts of selectivity than the other stationary phases.

Standard samples that underwent this procedure had an unexpected peak splitting
pattern that were consistent with previous observations in samples that had degraded under low
pH conditions. This pattern was missed on the plate reader due to its lack of a chromatographic
separation and lower selectivity when compared to mass spectrometry. This was first seen for
calcitroic acid that was prepared synthetically. This suggested that the conditions for the final
elution may be too harsh for calcitroic acid. A chromatogram of a standard calcitroic acid solution
that underwent SAX–SPE is shown in Figure 19. The use of acetic acid (a weak acid with a pKa of
4.75, higher than formic acid, 3.75) at a lower concentration was explored to prevent the
degradation of calcitroic acid in the eluent. Mass chromatograms of the standard solutions
prepared under different concentrations of acetic acid and formic acid were collected to see if a
reduction in degradation was available under milder conditions. The different eluent conditions
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were used for extraction of calcitroic acid out of standard samples. The ratios of the three peaks
under each set of conditions are summarized in Figure 20. A mild reduction in extraction
efficiency when 0.1% acetic acid was observed but the variance of the measurements remained
consistent allowing the procedure to move forward for tissue sample extraction.

Figure 19 – A chromatogram of a standard sample of calcitroic acid that underwent the strong anion exchange method. It was
found that there was unexpected signal from the standard sample that was attributed to the degradation of the sample under
acidic conditions.
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Figure 20 – A comparison of the ratio of the peaks observed in chromatograms of standard solutions of calcitroic acid dependent
upon the concentration and type of acid during the final elution step. It was found that the type of acid as well as its concentration
significantly contributed to the ratio of the observed peaks in the chromatograms.

Tissue samples were harvested from non-treated mice collected by necropsy and
underwent the optimized procedure removing large biological molecules. Samples were
homogenized in 1 mL of aqueous 0.1 M phosphate buffer pH 7.4 and centrifuged at 10000 rpm.
The supernatant was then collected and passed through 0.2 µm nylon filters to remove remaining
particulates. The samples were then evaporated by vacuum centrifugation for 24 h set to 30 °C.
The dried samples were then solvated in water, filtered through 0.2 µm nylon filters loaded onto
the liquid solid phase cartridge for extraction. The final eluent was 0.1 % acetic acid. The samples
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were then placed in the autosampler for HPLC–MS/MS measurement following the procedure
outlined in chapter 2. A summary of the extraction procedure is outlined in Schematic 15.

Schematic 15 – The workflow of the sample extraction procedure incorporating the strong anion exchange solid phase extraction.
The concentration of the acid used in the final elution was lowered from the initial 5% to make the method compatible with
calcitroic acid.

In the strong anion exchange extraction, the final eluent was able to be decreased in
volume from the initial 2 mL for loading to 250 µL. This decrease allowed for the preconcentration
of remaining species giving a signal increase in the final chromatograms. This effectively lowered
the limit of quantification by 8-fold during the procedure. This proved useful as is discussed
below.

4.5

On–Line Solid Phase Extraction
On–line solid phase extraction follows the same principles of an off–line method but allow

for a high throughput of samples that would be challenging in an off–line procedure. The
manifold interface of the autosampler to the liquid chromatographic column in our system allows
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for the incorporation of a SPE cartridge and methods for direct sample analysis were explored to
allow for utilization of this kind of high throughput system. The cartridge is placed in line with the
column and loaded in a slow flow rate step before the analysis. Then the valve position is changed
to allow for the eluent to pass over the cartridge disturbing the interactions of the species that
remain on the cartridge and pass them onto the column for the HPLC-MS/MS analysis. The
principles are identical to an off–line system but come with new parameters which must be
properly optimized for the analysis. The flow rates of the loading time, and wash step on the
cartridge have a similar counterpart but the elution becomes more challenging to account for the
dead volume between the SPE cartridge and column. In addition to this the elution conditions
become the initial conditions for the gradient that is used during the chromatographic
separation. For this reason, much of the optimization was conducted with the off–line extraction
method. The thought was that once a method was developed for the extraction procedure it
could be transferred to an on–line system if higher throughput were needed.
The initial solid phase extraction that was explored for the extraction of calcitroic acid, an
on–line reversed phase cartridge was used for the separation to remove background species from
the final mass chromatograms. The chromatograms of tissue samples that underwent
homogenization in methanol and centrifugation at 10000 rpm at 4 °C. The supernatants were
collected, filtered, and placed in the autosampler for analysis. This procedure used the initial
product ions for detection of calcitroic acid in its measurements. The chromatograms shown in
Figure 21 were collected using this method. An increase in the retention time from the initial
samples shown at the beginning of this chapter were observed due the dead volume between
the solid phase cartridge and the liquid chromatographic column. The complexity of the
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chromatograms was surprising after the extraction procedure. Much of the initial signal that was
observed in the samples that had only undergone an organic crash procedure remained in these
samples. The chromatograms contained peaks that corresponded individual product ions but not
the correct ratio that would be expected based on the fragmentation observed in the standard
samples. It was speculated that structurally similar compounds may share some of the transitions
that were used in the identification of calcitroic acid. The signal that was most unique (not a
dehydration of the precursor ion) 121.15 m/z was seen in very low intensity throughout the
procedure. This high amount of background after the extraction procedure suggested that an
alternative extraction procedure may be required for the simplification of the chromatographic
separation to prevent signal suppression or misidentification.

Figure 21 – A representative chromatogram of the separation that was achieved with an online solid phase extraction of calcitroic
acid. No peaks observed in the chromatogram corresponded with the expected retention time of calcitroic acid standard solutions
suggesting the reported signal was background.
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With the development of a strong anion exchange method for the separation of calcitroic
acid proving more promising that the reverse phase method, further exploration into on–line
solid phase extraction may be useful to increase the consistency of the extraction procedure and
reduce the manual labor currently present in the procedure. Substituting the cartridge of the on–
line solid phase extraction would allow for an increase in compatibility with the chromatographic
conditions. Additionally, a union introducing an aqueous mobile phase after the cartridge could
allow for minimal changes to the solid phase extraction eluent.

4.6

Molecular Filtration
The addition of methanol to tissue samples during homogenization was able to

precipitate many of the large proteins that are present in the matrix of the solution. Eliminating
large, charged biomolecules was still a concern for the strong anion solid phase extraction. Large
negatively charged species like deoxyribonucleic acid may make it through the proposed
extraction procedure and damage the column lowering its longevity. The introduction of a 10 kDa
molecular filter was added as a final filtration step before the evaporation. Ultracel-10 membrane
filters were purchased from Fisher Scientific. The extraction efficiency through the membrane
was explored. The extraction efficiency that was initially measured was far lower than expected.
It was observed that mouse plasma samples spiked with calcitroic acid did not contain a
quantity of calcitroic acid above the limit of detection after the molecular filtration. A
representative chromatogram of the findings is shown in Figure 22. It was speculated that
unspecific binding proteins may interact with calcitroic acid and then during the filtration step of
the procedure cause calcitroic acid to be removed from the filtrate. To explore this possibility the
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addition of the organic crash with MeOH instead of the phosphate buffer used in the previous
procedure was implemented. The thought processes being that the MeOH might be able to
disturb this interaction, dissociating calcitroic acid into the solution before the filtration.
Acetonitrile was also considered as a more nonpolar solvent that could be used during
precipitation and protein interaction disruption but was not compatible with the filters under the
desired solvent composition. The extraction efficiency of the spiked plasma samples that were
homogenized in methanol is shown in Figure 23. While substantial loss of the analyte was
observed the variance through the procedure would allow for precise calculation of the initial
calcitroic acid within tissue.

Figure 22 – A chromatogram of a spiked mouse plasma extract through the SAX-SPE method. The sample had a negligible peak
that came from the spiked standard. It was speculated that the signal was lower than expected due to unspecific protein binding
preventing the analyte from reaching the solid phase extraction method.
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Figure 23 – A comparison of A calcitroic acid sample with a standard solution that did not undergo membrane filtration. It was
found that there were significant losses during the process but due to the low standard deviation between the samples these
could be accounted for in the calculation of the initial concentrations of calcitroic acid in samples.

With the addition of the molecular filtration the final extraction procedure for calcitroic
acid in biological samples was finalized as the following procedure outlined in Schematic 16.
Tissue samples were homogenized in 1 g/mL methanol and centrifuged at 4 °C, 10000 rpm. The
supernatants were then collected and filtered through 0.45 µm then 0.2 µm and final 10 kDa
filters. The filtrates were then evaporated in a vacuum centrifuge over 24 h. The samples were
then reconstituted in water and filtered through 0.45 µm and 0.2 µm filter. The strong anion
exchange procedure described above was then used to extract calcitroic acid into 0.1% acetic
acid in MeOH. The samples were then diluted with water to match the starting composition of
the mobile phase composition. The extracts were then placed in the autosampler for LC–MS/MS
analysis.
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Schematic 16 –A final summary of the extraction procedure with the membrane filtration step. Samples were evaporated
between the membrane filtration and the SAX-SPE to allow for matching of the loading step solvent.

4.7

Stability of Calcitroic Acid Under Extraction Procedure Conditions
This study was confronted on multiple occasions with the instability of calcitroic acid

under acidic conditions. Samples were evaporated in the first designed procedure with just an
organic crash present. Depending upon the temperature of the evaporation it was seen in some
tissue samples the formation of other species in the final chromatogram than the expected
retention time and product ion peak ratio of calcitroic acid. Its procedure was then adjusted to
have a condenser added onto the vacuum to allow for the lower temperature of 30 °C. This was
not the end of the issues with calcitroic acid stability. Similar chromatographic peak splitting was
observed in the crude stock calcitroic acid used in the optimization of the new product ions in
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Chapter 2. This pattern arose again in later observations when the initial organic crash used in
the tissue extractions contained 0.1% formic acid. It was speculated, as the solvent is evaporated
from the filtrate, the pH of the solution becomes lower causing the degradation of the analyte,
interfering with its liquid chromatographic mass spectrometric measurement.
The final omission of formic acid was adopted for the remainder of the studies conducted
once this was observed. A similar acid instability was reported by the member of our group who
conducted the synthesis of calcitroic acid. The exact byproducts of this degradation were not
determined to be relevant for the goals of this project but are suspected to maintain major
portions of the initial analyte’s structure due to the chromatographic, and mass spectrometric
similarities. The increase in the retention time in the chromatograms also suggested an increase
in hydrophobicity during the degradation.

4.8

Quantification of Calcitroic Acid Concentration is Tissue Samples
Throughout the optimization of the extraction of calcitroic acid, measurements were

collected that informed the parameters for the analysis. The initial sample of interest was of
mouse plasma to determine the levels of circulating calcitroic acid. Understanding the
concentration that was present in the plasma would speak toward the localization that could be
expected in other tissue samples if the primary site of the metabolism were the hepatocytic cells.
Mouse plasma samples were explored using the final method described above in Schematic 16.
A representative chromatogram of the plasma samples is shown in Figure 24. It was observed
that even with the preconcentration gained with the solid phase extraction, and background
suppression from the separation methods, calcitroic acid was not present at a concentration
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above the determined limit of detection in plasma samples. This suggests that the circulating
concentration of calcitroic acid would be lower than the determined biological active
concentration. This would suggest that if any site downstream of the liver in the intestinal track
does not utilize the biological activity of calcitroic acid. To assure that calcitroic acid was not being
suppressed by the final matrix of the samples, calcitroic acid as a spike to the concentration of
10 µM was added to the sample. The results can be seen in Figure 25. The peak associated with
calcitroic acid was observed in these chromatograms suggesting minimal signal suppression was
occurring.

Figure 24 – A chromatogram of a native mouse plasma sample worked up through the SAX-SPE extraction procedure. Several
peaks of a single product ion at retention times not matching standard solutions of calcitroic acid were observed. It was concluded
that calcitroic acid was not present in theses samples at a concentration above the limit of detection.
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Figure 25 – A chromatogram of a calcitroic acid spiked solution mouse plasma to measure the extraction efficiency through the
procedure. It was found that when a sample was spiked to a concentration of 10 µM the measured concentration after the
extraction was 8.86 µM giving an 88.6 % recovery through the procedure.

To further explore the activity and localization within the intestinal tract of calcitroic acid,
liver, large and small intestinal samples were collected and worked through the extraction
procedure the determine the native concentration of calcitroic acid. A collection of
representative chromatograms is shown in Figure 26. It was observed that no signal with the
corresponding product ion ratios and retention time corresponding to standards of calcitroic acid
was observed within the study. While no signal for the corresponding retention time was
observed several other peaks came through in high intensity during. The large intestinal samples
appeared to have high signal at a later retention time than would be expected for the native form
of calcitroic acid. Due to the high specificity of the extraction and separation method it was
postulated that the molecules responsible for this signal were most likely closely related to
calcitroic acid in structure and may be unidentified metabolites of calcitroic acid, possibly a
conjugate. If calcitroic acid was in a conjugated form that could have consequences to the
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retention time as well as the fragmentation through the measurement. A spike of calcitroic acid
to assure that the retention time was not shifted due to the matrix conditions was conducted.
Figure 27 shows the corresponding spiked liver sample after the extraction procedure. It was
observed that the spiked sample did not have a tangible change in retention time that would
account for the signal that was observed in the chromatograms. To further explore this
hypothesis, mice were supplemented with cholecalciferol (vitamin D3) and a second set with
ergocalciferol (vitamin D2) to see if quantities of Vitamin D affected the circulation of calcitroic
acid.
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Figure 26 – A collection of chromatograms of tissue samples that underwent the described strong anion exchange extraction
procedure. Several peaks were observed in the chromatograms that contained fragmentation seen in calcitroic acid. The
retention time as well as the product ion ratios did not match what had previously been seen in chromatograms of calcitroic acid
standards. A standard sample of calcitroic acid is shown at the bottom for comparison of the retention times and a sense of scale
of the signal intensity.
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Figure 27 – A chromatogram of a liver extract sample that was spiked with calcitroic acid after the extraction procedure to
compare the retention time of the native signal with the standard under these matrix conditions. It was observed that the
retention time of calcitroic acid was not affected by the biological matrix in an of the samples measured.

To explore the possibility of high levels of excretion of calcitroic acid, a mouse was
provided with a dose of vitamin D2 to monitor the effect of catalysis of calcitroic acid. One set of
mice were provided with a 5 mg/kg intraperitoneal (IP) injection, and feces collected over of 24
h. Afterwards samples were worked up through the described extraction procedure before
HPLC–MS/MS quantification. A set of representative chromatograms are shown in Figure 28. The
top chromatogram in the figure represents the HPLC–MS/MS method that was developed based
on the fragmentation of [M+H]+ and below the fragments of the dehydrated form of calcitroic
acid. It was observed that the fecal samples of the mice appeared comparable to large intestinal
samples that were collected of the untreated mice. This suggests that predominant signal that is
observed in these samples comes from the contents of the intestinal tract and that the signal is
independent of the vitamin D exposure of the animal. To confirm this finding feces and urine
samples of mice given cholecalciferol were explored.
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Figure 28 – A set of two chromatograms showing both the [M+H]+ (bottom) and the dehydrate product ions (top). Several peaks
were observed in both chromatographic methods thought the ratio of intensity seems to change between the two methods of
detection.

Mice were given a 2.0 mg/kg of cholecalciferol orally in vegetable oil. Urine and feces
samples were then collected in two 24 h fractions over 48 h. the samples underwent the
described extraction procedure before HPLC–MS/MS analysis. The corresponding mass
chromatograms are shown in Figure 29. Consistent to the previous set of organ samples, no
calcitroic acid was observed above the limit of detection in either set of samples. What was found
is a similar pattern in the chromatographic peaks between the feces samples and the large
intestinal samples. The previous colon sample did not have the feces removed before the
extraction and thus contained feces in the samples. The resulting chromatogram seems to reflect
this design choice in the inclusion of compounds in the final chromatograms that is attributed to
the feces. This suggests that the peak that was present in the colon samples that was thought to
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be structurally similar to calcitroic acid is truly present in the feces samples and its concentration
is independent of the concentration of vitamin D in the mouse’s diet.

Figure 29 – A set of two chromatograms of the same fecal sample from a mouse given an oral dose of vitamin D3. The sample
follows a similar pattern to what was seen in the mouse given vitamin D2. The sample’s chromatogram contained similar peaks
as the large intestinal sample collected in non-treated mice.

Future studies that would build upon these finding could incorporate a direct dose of
calcitroic acid provided to the studied mice. This would eliminate the possibility of vitamin D
excretion through other pathways and would allow our group to speak more directly towards the
circulation of calcitroic acid before excretion. Including this dose of calcitroic acid would more
directly measure the possibility of conjugation of calcitroic acid leading to changes in the signal
that was speculated to be corresponding to other structurally similar species. If it were found
that a strong link between the previously measured signal and calcitroic acid was observed
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carbon labeled calcitroic acid could be substituted into the procedure to affect the mass
spectrometry and allow for a comparison of the native calcitroic acid and the supplemented
quantity of calcitroic acid.

4.9

Conclusion
The quantification of calcitroic acid within tissue samples provide more challenging than

other molecules that our group has explored in the past. Several separation methods were
included beyond the initial method of liquid chromatographic separation paired with the
selectivity gained from the tandem mass spectrometric detection to allow for the avoidance of
forms of signal suppression or misidentification due to structural similarity. Several additional
extraction procedures were explored to improve the chromatography during this study.
Optimization was done on a strong anion exchange method to allow for eluent conditions that
were compatible with the stability of calcitroic acid. A working method of separation was
determined for calcitroic acid that accounted for hydrophobic species that may have previously
been reaching the liquid chromatographic separation. In addition, the incorporation of a small
molecule membrane filtration when paired with an organic crash allowed for the removal of
proteins and other larger charged species from interfering with the solid phase extraction. The
final method was implemented on a series of tissue and biological samples and found that
calcitroic acid was not present in a form that was above the limit of detection for the developed
method. Mice that were provided with vitamin D before the samples were collected showed
similar negligible levels of calcitroic acid.
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Further optimization to the conditions used for the solid phase extraction can be
conducted to further lower the limit of detection of the method as well as modify the method
for the implementation of an on–line extraction, drastically increasing the throughput of the
study. To first determine if the additional optimization is necessary for greater insight into
calcitroic acids localization, the identification of the later retention time peaks within the large
intestinal samples will need to be confirmed as related to calcitroic acid. A study where mice are
provided with calcitroic acid and biological samples and tissues are collected and undergo the
extraction procedure will provide insight into the vitamin D clearance process. Previous studies
suggest that the expected product of vitamin D excretion would be calcitroic acid. This study adds
to that body of work suggesting that due to improvements in the chromatographic separation
that our method provides we may be separating out conjugated forms of calcitroic acid that have
not been previously identified by the scientific community. Further confirmation with calcitroic
acid in vivo and in vitro studies will explore these finding.
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5

Derivatization Reactions of Calcitroic Acid

5.1

Introduction to Vitamin D metabolite derivatization
Derivatization reactions have long been a part of the measurement of vitamin D in assays.

Radiolabeled vitamin D was integral for many of initial studies which identified vitamin D
metabolite60,

61.

Different types of derivatization reactions have been able to adjust the

properties of vitamin D to match the needs of the type of measurement being conducted62. Often
the modifications changed the retention with in a chromatographic separate, adjusted the
volatility for gas chromatography, shifted the absorbance to allow for the measurement with
absorbance spectroscopy, or increased the molecular mass and increased the ionization for mass
spectrometry63, 64. This chapter summarizes the studies performed to explore advantages of
derivatization reactions for calcitroic acids detection. Methods that have incorporated
derivatization reactions into the analysis of vitamin D species have reported the benefit of 10fold to 100-fold increase in signal intensity62, 65. Our work explored if these advantages could
simply be applied to our method of measurement.
While the advantages of a derivatization reaction seem quite appealing for any chemical
analysis, there are significant downsides that can hamper the ability of a quantitative analysis.
When a chemical reaction is included into an analysis the efficiency of the reaction now governs
the measurements that are made on the reaction. Matching the exact reaction conditions during
replication can cause variance from scientist to scientist or interday variance. Additional time and
labor are also needed to do these analyses. While some level of specification is expected with
the different classes of derivatization reactions, side reactions are also very common in samples
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with high matrix complexity like biological samples. Other species can undergo similar reactions
causing excess reagent to be required for each sample63. Depending on reagent use and the load
capacity of columns used during the analysis, and volatility of derivatization reagents, this can
have ramifications in the column longevity and the quality of chromatography.
The class of derivatization reagents that were explored in this portion of the study were
called dienophiles. These types of molecules were first reported by Cookson et al. as a
derivatizing agent66. The general form Cookson reagent reaction can be seen in Schematic 17.
The final structure retains some of the conjugation of the starting reactant but allows for
additional moieties to be included in the final structure, bestowing the red shift that is desired
for absorbance spectroscopy67. Alternatively, the shift in the m/z ratio that these molecules
provide can move the analysis of an analyte into a lower background region of a mass spectrum.
The amide functionalities also can assist in the ionization of derivatized products65.

Schematic 17 – A representation of the dieneophile reagent acting upon the analyte through a Diels-Alder reaction.

5.2

Instrumental Considerations Metabolite Analysis
One trait that is commonly adjusted in these derivatization reactions, is the volatility of

analytes allowing for gas chromatographic analysis. The column dimensions of gas
chromatography led to an improvement in the separation over liquid chromatography. While the
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separation of our method could be improved, the goal was to explore removing molecules that
shared a precursor ion with calcitroic acid but did not contain the diene motif. To accomplish this
derivatization, reagents were explored that would not only change the mass of calcitroic acid but
the red shift in absorbance to allow for a simple spectrometric detection. Being able to use an
UV-VIS spectrometer would allow for less optimization during the analysis, which at this point in
the study was still underway. While calcitroic acid has several unique functional groups, the hope
would be to operate upon the conjugated system. This functionality unlike the carboxylic acid or
hydroxide moieties was far less common among other molecules, adding a layer of selectivity to
the analysis.

5.3

Applications of Derivatization Reactions on Calcitroic Acid
The specific dienophile that was used for this study was 4-[2-(3,4-Dihydro-6,7-dimethoxy-

4-methyl-3-oxo-2-quinoxalinyl)

ethyl]-3H-1,2,4-triazole-3,5(4H)-dione

(DMEQ-TAD).

The

proposed reaction between calcitroic acid and this species is shown in Schematic 18. The
absorbance of calcitroic acid had previously been measured at the wavelength of 264 nm as
reported in Chapter 4. With the addition of the DMEQ-TAD tag, the absorbance was expected to
shift higher, close to the λmax of the DMEQ-TAD, 370 nm.

82

Schematic 18 – A representation of speculated reaction between calcitroic acid and the DMEQ-TAD forming the fluorescent
derivative used for UHPLC measurement.

The reaction conditions were taken from the work of Hagashi et al.68. The reaction was
monitored over 3 h and ran at room temperature with a large excess of the DMEQ-TAD to assure
conversion to the final product. TLC was performed with the starting materials as well as the
reaction at 30 min and 3 h. The TLC is shown in Figure 30. The derivatization reaction formed two
fluorescent products in addition to the starting material (Figure 30A). Detection at 254 nm also
showed the conversion of calcitroic acid. 1H-NMR spectroscopy and HPLC–UV/VIS were
conducted for further analysis. The 1H-NMR spectra are shown in Figure 31. We monitored for
the disappearance of the diene peaks which are visible between 5.0 - 6.3 ppm for calcitroic acid.
While this change seemed to occur, the aromatic protons for the adduct were missing, which
brings concerns on material stability. However, limited stability of the adduct in deuterated
chloroform might has influenced the analysis.
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A

B

Figure 30 – Thin layer chromatogramphy in 1:9 MeOH:EtOAc comparing the starting materials to the shwon on the right and left
under 365 nm, and 254 nm light respectivily. The loss of the starting material and the formation of a central peak between the
retention of the starting materials suggested the reaction had occurred.
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Figure 31 – A set of spectra reflecting Calcitroic Acid, Reaction after 2 h, and the Cookson reagent, DMEQ-TAD, top, middle, and
bottom, respectively.

To further confirm these findings, HPLC analysis was conducted on the derivatized sample
of calcitroic acid as well as the starting materials using the indicated conditions in Figure 32. An
overlay of the collected UV chromatograms shows that the starting materials contained all the
peaks observed within the reaction mixture. The starting DMEQ-TAD reagent contained several
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peaks that suggested low purity and possible degradation of the sample before its use in the
reaction. This may have led to a loss in activity and product yield during the reaction.

Figure 32 – An overlay of the starting materials of the reactions with the reaction mixture sample run for 2h. No peaks that were
seen the reaction mixture were unaccounted for in the starting material chromatograms.

Interestingly, the overlay of spectra from calcitroic acid and the reaction mixture showed
the starting material in both samples. At this point the derivatization of calcitroic acid with
DMEQ-TAD was inconclusive. Further optimization has not been conducted but the mild reaction
conditions for this reaction make it an ideal candidate for its use with calcitroic acid. The relatively
short reaction time would allow for this type of reaction to be well utilized with large sets of
samples. While these advantages paired with the simplicity of spectrometric measurement may
prove useful, further optimization needs to be conducted on the reaction conditions and the
controls in place to assume conversion to the red shifted product.

5.4

Isotope Labeling of Calcitroic Acid
Calcitroic acid is a naturally occurring biological species. Its natural occurrence can make

the choice for standards to use in its analysis challenging. Selecting of other biologically available
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compounds can be affected by the endogenous concentration. At the same time working with
samples where calcitroic acid may already be present in some concentration can prevent the
measurement of the quantity that is present after administrating into an animal during a study 63,
69. One

clever method for addressing these issues is to use heavy isotope labeling paired with the

mass spectrometric detection. Mass spectrometers can distinguish

13C-labeled

calcitroic acid

from natural occurring calcitroic acid. Heavy isotope labeling can prevent ionization differences
between the analyte and internal standards. They allow extraction efficiency of procedures to be
identical allowing a high accuracy in the correction done to the initial concentration of the native
analyte. Chromatographically, there is a disadvantage to these standards. Ultra-highperformance liquid chromatographic separations are not typically able to well resolve
compounds separated by a single mass unit.
Our group synthesized isotope labeled calcitroic acid for the use as an internal standard
for the studies that would be conducted within animal models. The synthesis route follows
previously published work by our group70. In future work isotope labeled calcitroic acid will be
used to further explore the clearance pathway of calcitroic acid in mice. As discussed in Chapter
4, complex chromatographic patterns were observed for calcitroic acid when exploring mouse
organ samples. Peaks that did not correspond to the expected retention time of calcitroic acid
appeared in the chromatograms of samples that had undergone an extensive extraction
procedure. It was speculated that other metabolites of calcitroic acid of structurally similar
compounds could be present within the samples after the work up. To confirm the connection to
the circulation concentrations of calcitroic acid, 13C-labled calcitroic acid could be administered
to distinguish metabolic products of calcitroic acid from other structurally similar compounds. If
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peaks that had not previously been confirmed in connection to calcitroic acid increase in area,
this will speak towards their relationship to vitamin D metabolism. Similar studies can be
conducted with isotope labeled vitamin D to determine the clearance of the vitamin D to see if it
is a structurally similar compound that could follow a different metabolic pathway than the one
that leads to calcitroic acid. With the identification of metabolites through the in vivo studies,
paired in vitro studies as described in Chapter 3 will confirm the conversion of these species and
metabolic rates of formation can be determined.

5.5

Conclusion
Vitamin D metabolite identification was built on a series of radiolabeling methods paired

with several derivatization reactions to allow for the separation and identification of species
based upon their physical properties. At the heart of these methods is radiolabeling, which
allowed for low limits of detection with almost no background signal to the measurements. While
these methods have many advantages the synthesis of these compounds can be time consuming
and costly for research projects. New advances in mass spectrometry allow for a new view into
vitamin D metabolism with selectivity from fragmentation patterns. While this is a powerful
method as shown in previous chapters, the instrumentation comes with a level of sophistication
and complexity to the results. Our group set out to explore alternative methods that could
supplement the measurements being conducted with the mass spectrometric detection. It was
found that Diels–Alder reagents could be used to shift the wavelength of compounds containing
the diene motif providing selectivity for this characteristic and shifting the absorbance into a
region where other biological samples do not absorb. During this reaction, Impurities in the
derivatization reagent affected the reaction efficiency. Additional optimization and controls
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would need to be put into place for the reaction to be utilized in routine analysis, preventing
further exploration into the topic.
Heavy isotope labeling offers a unique method of the measurement of extraction
efficiencies within individual samples. Improving upon the accuracy of individual measurements
of calcitroic acid within a given sample. Our group synthesized 13C calcitroic acid for the purpose
of internal standards of studies and monitoring calcitroic acids pathway, distribution, and
clearance in animal models. Future studies will use these samples paired with the developed
mass spectrometric detection to determine calcitroic acids localization of possible metabolites in
in vivo studies.
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6

Modeling Inflammatory Bowel Disease
Animal models are a powerful tool in understanding the efficacy of drugs and the

biological role of endogenous molecules. In vivo studies account for many factors that are
excluded for simplicity in an in vitro model such as the lack extracellular signaling pathways from
a typical inflammatory response. In this set of studies our group set out to adopt a model of
inflammatory bowel disease. Inflammatory bowel diseases have had a global increasing trend
within the past decades71. Kong et al. have shown a relationship with the vitamin D receptor and
inflammatory bowel disease72. We hoped to determine whether calcitroic acid plays a role in the
mitigation of inflammation within the colon. If it were found that calcitroic acid was effective in
mouse models, novel compounds could be designed with higher efficacy to help combat this
disease.

6.1

Introduction to Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) follows an inflammation pathway that can cause acute

distress as well as chronic scar tissue formation leading to long term effects on digestion and
other illnesses such as colon cancer. Inflammatory bowel disease can be broken down into two
diseases, Crohn's disease, and ulcerative colitis. IBD has a multi-causational, though it is
speculated that there is a genetic component that leads to induction of the inflammatory
response through an overactive immune system. One aspect of the pathophysiology of the
disease is the exposure of regions of the intestinal tract to bile acid acting as an irritant inducing
inflammation. Common compounds currently used in the treatment of IBD include
corticosteroids such as prednisone and dexamethasone73. These compounds were used as
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positive controls in the design of the animal model below. They act by disrupting cytokine
response preventing the cascade of recruitment74, 75. The blocking of cytokines prevents the
histological signals of inflammation from occurring. Steroidal treatments cause suppression of
the immune system, which leads to other applications of these drugs in treating autoimmune
diseases but can have significant side effects76. Developing a drug based on the response of the
calcitroic acids activity on the vitamin D receptor would allow for greater specificity over
traditional corticosteroids.

6.2

Experimental Design
Our research in this section was designed to determine the effect of calcitroic acid on

induced colitis in mice to see if there was a reduction similar to the response observed with
currently used corticosteroids such as dexamethasone and prednisone. Our goal was to
implement a model using swiss webster (CFW) mice, an out-bred stain, to demonstrate the
robustness of the model. Outbred mice contain more genetic variance within the population
leading to a more accurate representation of human populations. The initial model was based on
studies that were using inbred mice, and the procedure was modified in the way described below
to account for the difference in the colonies used77.
CFW mice were purchased from Charles River for the use during the study. The mice were
separated into groups of positive control (corticosteroid treated), and vehicle. The mice were
housed in groups of four to accommodate for social tendencies. Bedding material was provided
as an enrichment for each cage. Each set of mice that were used in the study were given seven
days to acclimate to the new environment after relocation. Mice were then administered a dose
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of corticosteroid, or vehicle daily depending on the group. Weights were collected for each
mouse daily throughout the study. Photographs of the coat quality were taken daily and
compared between the two groups. It was found that this measure seemed independent of the
other measures of colitis severity during the study and thus was omitted from the findings. On
the third day of each study, mice were anesthetized using isoflurane for an installation of the
chemical irritant to induce colitis. This model was designed to imitate the type of inflammation
that would be observed in ulcerative colitis. 2,4-dinitrobenzene sulfonic acid (DNBS) was used
during the first set of these studies to serve this purpose. The number of installations and
concentration varieties during the optimization of this model and is described in Section 6.4. The
mice were monitored over the course of five days after the initial installation, or seven days after
the first dose of the respective compound. On each day, the mice were given a dose of
corticosteroid, or the vehicle dependent upon their group. On the final day of the study the mice
were euthanized through CO2 asphyxiation and spinal dislocation. This was followed with
exsanguination for ease of the necropsy. Colons were excised, photographed, and measured in
length before and after the cleaning procedure. The colons were rinsed with a PBS buffer and
stored on ice in PBS before homogenization.

6.3

Quantification of Colitis
A preliminary study conducted by our group identified several markers that could be

utilized for the analysis of inflammation within this model. The first measure that would be
monitored throughout the study was the weight of the mice. Besides the ramifications of this
measurement for the humane endpoint of the study, set to be 25% total loss of body mass, this
measurement allowed for a sense of distress that the study was placing onto the animal signaling
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eating and drinking pattern. Coat quality hoped to speak towards the same measure by
measuring the habitual grooming pattern of mice and how this could signify the wellbeing of the
animal. Movement patterns were explored during the early parts of the study and would follow
the tracking of animals. Animals were placed into a container and monitored for 90 sec time
intervals. Their position relative to the edge of the container suggested regular survival instinct
to avoid the center of the container for predatory exposure. Finally hematological data and
histology was planned for the study based on the initial finding with BALB/c mice suggesting that
a difference in the recruitment of immune cells to the site of inflammation was visible.
Differences were observed in the circulating concentration of granulocytes with mice that were
treated with the chemical irritant. This measure was planned to be used once the activity of
myeloperoxidase (MPO) expressed by granulocytes was determined. MPO activity can be
determined by its ability to form perchlorate from hydrogen peroxide78. The perchlorate then
acts as an oxidizing agent dimerizing the o-dianisidine shifting its absorbance to 460 nm for
spectrometric measurement.
Each colon was transferred from the animal facility along with the blood samples when
appropriate for histological and biochemical assays. Blood parameters were measured at the
Medical College of Wisconsin. The colon samples were then transferred to a new vial and massed
without the PBS buffer. The initial study that was conducted to determine the activity of MPO
used a fragment of colon that was weighted, homogenized, and analyzed. A change to the
procedure was done to account for the distal localized nature of the inflammation within the
colon. The entire colon was used during the procedure and the protein concentration was
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determined with a bicinchoninic acid (BCA) assay to enable a uniform protein concentration for
all colon samples.
The principle of the BCA assay operates on the reduction of Cu2+ present in the assays
reagents to control the metal chelation leading to a shift in the absorbance of the reagents. A
general mechanism of the procedure is shown in Schematic 19. cysteine, cystine and tryptophan
reduce copper ions added in the reaction changing its oxidation state79. The cuprous then can
form a complex with the chelating agent changing the absorbance maximum to the wavelength
of 562 nm. The absorbance can be compared to a calibration curve generated from standards to
determine the amount of protein that was present in the original sample.

Schematic 19 – Representation of the reduction of coppric to copprous by amino acids. The reduced form is then chelated to
form a redshifted complex.

A solution of 50 mM phosphate buffer at pH 6.0 with a detergent of 50 mM
hexadecyltrimethylammonium bromide was used to homogenize the samples. A handheld
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homogenizer was used for the homogenization step within a biological hood. Colon homogenate
samples were then transferred into a centrifuge tube and centrifuged at 10000 rpm at 4 °C from
10 min. Aliquots of the supernatants were then diluted 8-fold and 16-fold in two sets and a BCA
assay was conducted on each of the samples to determine the total protein concentrations of
the supernatants.
In the BCA assay, a ladder of bovine serum albumin (BSA) was prepared from solid stock
standards to generate a calibration curve of protein. The two reagents were then added to a 96
well plate and 4 replicates on each standard and sample were measured using the Tecan plate
reader at the wavelength of 562 nm. Samples were compared to the calibration curve to calculate
the protein concentration. Informed by the initial supernatant concentration in protein, each
sample had an aliquot diluted to the concentration of 200 µg/mL for use in the myeloperoxidase
(MPO) Assay. Diluted supernatant samples were stored at 4 °C during the solution preparation
of the MPO assay.
A daily standard solution for the hydrogen peroxide solution was prepared to a
concentration of 0.0024% from a 35% v/v stock. The phosphate buffer that was prepared for the
BCA assay was utilized for the dilution step of this assay. O-dianisidine dihydrogen chloride was
prepared at a concentration of 167 µg/mL in phosphate buffer and sonicated for 30 min to
dissolve in the buffer. 8 µL of the BCA assay concentration adjusted colon supernatant was
transferred to a 384 well plate containing 62 µL of the o-dianisidine solution. The reaction is
initiated with the addition of 10 µL of the hydrogen peroxide solution prepared above. The
conversion of the o-dianisidine was mitigated by a secondary oxidation after the hydrogen
peroxide is converted into hypochlorite. The general process of this reaction is shown in
96

Schematic 20. The product of this reaction shifts the absorbance to the λmax to 460 nm. The plate
is then measured over a 15 min period in the plate reader in 30 sec intervals. Four replicates on
each homogenate sample were conducted for each of the MPO assays described in this chapter.

Schematic 20 – The chemical reaction that occurs in the designed myeloperoxidase assay. Hydrogen peroxide is oxidized
enzymatically into hypochlorite which then acts upon the o-dianisidine.

6.4

Experimental Design Optimization in Studies
While the study procedure for IBD has been demonstrated by previous research groups

using inbred mice, our group hoped to define a model with outbred mice that described the
efficacy of compounds to reduce inflammation. While the genetic variance of the population
was an advantage towards a compound's robust response to different genotypes, it led to
complications in transferring the method which required further optimization of the study. This
section outlines the series of modifications to the study that were conducted to allow for the
implementation of the outbred CFW mice within our study.

6.4.1 Optimization Irritant Concentration
The first study that was conducted was set to determine the efficiency in inducing colon
inflammation in the CFW mice. A literature dose of 200 mg/kg DNBS for BALB/c mice resulted in
a poor response in the single installation of the DNBS prompting a second dose of 200 mg/kg
during the second day of the study. Two groups of six mice underwent this procedure. One group
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that was provided with dexamethasone and the second group given the vehicle, both provided
through IP injection. The diluent for the drug was in 5:40:55 DMSO:polyethylene glycol 400:
phosphate buffered saline. In this study mouse weights were monitored for the five days
following the first dose of the DNBS.
The weight changes are shown if Figure 33. The red dashed line represents the expected
weight loss of mice in the study that had a proper installation of the DNBS inducing colitis. The
negative control group average percent weight loss was found to be -21.5% ± 2.1% while the
dexamethasone treated mice had an average percent weight loss of -7.1% ± 3.8%. By the fourth
day of the study, there was statistical significance P < 0.001 between the treated group and the
non-treated group suggesting a reduction in inflammation. Colons were collected from the
necropsy and photographed for visual signs inflammation. The images are shown in Figure 34.
Widespread inflammation was observed with two of the mice having severe colon inflammation.
Fecal consistency also varied widely among the group suggesting that the consistency of the
dexamethasone treatment had high variance.
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Figure 33 – Weight loss of the mice as a percentage of the initial body weight at the beginning of the study. The two graphs on
the left represent the indiviual mice within the study and the graph on the left shows the groups combined for statistical analysis.

Figure 34 – Images of the colons in the positive control group of the intial IBD study. The explected length of an untreated colon
would be near 9.5 cm while all members of this group fell below that meaure.
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Finally, MPO assays were conducted following the procedure described above to
determine the oxidative enzyme activity in the colon homogenates. A set of absorbance of
samples run over 15 min is shown in Figure 35. The negative control represents mice that were
provided with the vehicle and DNBS, the positive control group received dexamethasone and
DNBS, the negative control received no DNBS. As was expected, the group that did not receive
the DNBS installation have very low activity of oxidative enzymes in their colon homogenates. It
was unexpected that the group that received dexamethasone did not have a significant reduction
in inflammation when compared to the group that were untreated. It was of interest that the
two mice that had strong visual inflammation scores were seen to have higher levels of
inflammation than the negative control group. It was speculated that the vehicle group may have
not had a strong enough inflammation response for the dexamethasone to be able to reduce the
inflammation. The study was repeated with two groups during the same week to see if the
deviation of the visual inflammation and MPO activity was truly an outlier or the expected
response of the assay.
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Figure 35 – Collection of MPO assays conducted on the three different groups of the intial study. The left side of the graph contains
both the mice given vehicle and the chemical irritant, DNBS while the figure below it shows mice with no chemical irratant. The
graph on the right is the MPO assay conducted upon mice that were given 1.0 mg/kg dexamethasone after installation of DNBS.

The comparison of the two groups by weight is shown in Figure 36. While not significate,
it was observed that a trend between the two groups was observed two days after the
installation. This did not carry through the remaining days of the study and the two groups
converged on similar % weight loss. It was also noted that two mice that were in the vehicle group
did not maintain a weight above the humane end point and were removed from the study before
the final day. The summary of colon images can be seen in Figure 37. Of the mice that were alive
during the final day of the study, one mouse in the vehicle group and one in the positive control
had high visual inflammation scores. Minor inflammation was observed in one colon from the
dexamethasone group. The MPO assay was conducted following the previously described
procedure on colon homogenates shown in Figure 38. No significant difference in the activity was
observed between the two groups. There were concerns about the concentration of the DNBS
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but the requirement for an elevated oxidative response in the sample suggested that
modification to the corticosteroid concentration may be better suited for separating these two
groups.

Figure 36 – A comparsion of the treated and vehicle groups of mice in the replicate of the intial study. No statistical signifcance
was seen between the two groups.

Figure 37 – Colon images of the replicate of the initial sample conditions. The severity of the inflamation seen in these groups
was greater than what was measured in the first study.
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MPO Assay Positive Control and Vehicle

Figure 38 – Overlay of the MPO assay indiviual colon homogenates for the vehicle group (black) and the positive control group
(red).

To explore whether the concentration of the dexamethasone could be increased to
reduce colon inflammation within the positive control group, mice were treated with 5 mg/kg of
dexamethasone. The resulting comparison with a vehicle group is presented in Figure 39. The
standard deviation of each of these groups was very large. Each of the individual weights
throughout the study is shown in Figure 39 as well. DNBS installation did not appear to be
effective in two mice, showing low weight loss over the study. It was unexpected that the visual
determination of inflammation did not correspond well to the weight loss data collected over the
study. The images are shown in Figure 40. Fecal consistency varied between the two groups,
adding to the concerns of correlation between weight loss and colon inflammation. The MPO
assay results conducted with colon homogenates are shown in Figure 41. The inconsistency of
the two groups suggested the design of the MPO assay not sensitive enough to determine the
oxidative enzyme activity.
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Figure 39 – Comparison of the vehicle (blue) and positive control group (red) now provided a higher concentration of 5 mg/kg
dexamethasone.

Figure 40 – Collected colon images of mice during the study (V for vehicle and PC for the postive control). The postive control
received the higher concentration of 5 mg/kg dexamethasone.

104

Figure 41 – MPO assay overlay of the higher dose 5 mg/kg dexamethasone group (red) compared to the vehicle (black).

6.4.2 Removing Nonchemical Inflammation

The high level of variance of inflammation within both groups rose concerns that the
method of delivering the compound might be inducing a physical irritation near the site of
interest. The 100 µL IP injection was considered a large quantity for the administration of a
propylene glycol solution that may not have proper clearance over the time before the next dose.
Alternative formulation was performed with a 1:15 (2-Hydroxypropyl)-ß-cyclodextrin:PBS
solution containing 5% DMSO for improved solubility of the dexamethasone. The dose was held
constant from the previous study of both the dexamethasone and DNBS. The weights were
collected following the same procedure as described above. The percent weight loss is shown in
Figure 42. Similar to what was observed between the past studies, no significant difference
between the two groups was observed. The standard deviation of the two groups both seemed
lower as all mice in the study underwent a colitis-like response from the DNBS. All mice within
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the model had a visual inflammation response that would be expected from the induction of
colitis as shown in Figure 43. The MPO assay data collected with colon homogenates are shown
in Figure 44. The response between the two groups was not found to be significant. This was
expected based on the weight percent weight loss, as well as the visual inflammation and fecal
consistency measures. One colon, V3, in the assay still had a significant higher oxidative enzyme
activity. This mouse was considered an outlier of the assay. It was concluded that the formulation
was not the reason for the data inconsistency. At this point in the study development there were
two issues that needed to be addressed before this study could be used to investigate new
compounds. The MPO assay had to be adjusted so that the variance between measurement
would allow for comparison between the two groups. Beyond that problem, the inflammation
severity within the vehicle group needed consistency to allow for the efficacy of the positive
control to be shown.

Comparison of Weights Vehicle and Positive Control

Figure 42 – A comparision of mouse weights indivual (left) and grouped (right) for mice treated with a new vehicle.

106

Figure 43 – Colons collected from the two groups of mice vehicle (top) and dexamethsone (bottom). The varience in length as
well as localized inflamation was observed in this study similar to previous studies.

MPO Assay Diluent Change

Figure 44 – The MPO Assay overlay of the postive control (red) and vehicle (black) groups. Several colon homogenates had higher
than expected activity based on the visual and weight loss observed during the study.
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6.4.3 Colon Homogenate Preparation
Adjustments upon the sample preparation procedure were posed to see if less colon
washes could prevent the loss of oxidative enzyme activity. It was speculated that the rinse of
the colons with PBS could have removed most granulocytes that would be present within the
colon and caused greater variance in the MPO assay measurements. The new study that was
conducted hoped to explore the activity of colon homogenates that used mechanical removal of
feces alternative to solvent rinses.
Two groups of n = 4 mice were separated and treated with vehicle and dexamethasone
prepared at 5 mg/kg daily over the study. The percent weight loss is shown in Figure 45. The
percent weight loss between the two groups was not significant. The corresponding colons are
shown in Figure 46. Large sites of discoloration and enlargement were seen in all colons of
both groups of the study. Fecal consistency was soft for all the mice that underwent necropsy.
The oxidative activity of colon homogenates is shown in Figure 47. These data correlate well
with the visual inflammation that was observed but not with what was expected based on the
percent weight change. The variance between individuals within each group was very low
excluding the outlier P3. Due to this improvement of the MPO assay, all future studies
incorporated the non-solvent based fecal separation.
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Figure 45 – Weight lose of inividual mice (left) and grouped (right) as a percentage of the initial weight at the beginning of the
study. No statistical difference was observed between the two groups.

Figure 46 – Colon images of mice in the vehicle group (top) and the positive control (bottom). High levels of inflamation were
present in both groups.
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MPO Assay No Solvent Wash

Figure 47 – MPO assay overlay of indiviual mice from the vehicle and positive control groups. The colons underwent manual
fecal remove to try and preserve oxidative activity.

6.4.4 Corticosteroid Administration
Intraperitoneal injection (IP) of compounds was used for all previously described
studies. Due to the variance of data within the studies it was posed that the site of injection
may be too close to the intestinal tract and may interfere with the installation of DNBS. To
address this issue, IP injections were changed to an oral administration of dexamethasone. An
oral dose 5.0 mg/kg of dexamethasone was prepared in 5:95 ration of polyethylene glycol 400:
2.5 % aqueous solution of hydroxypropylmethylcellulose (HPMC). Mice were treated on the
same schedule as described above.
The dose of the dexamethasone was maintained in hopes of inducing a significant
reduction of inflammation in the treated group. Under these changed conditions groups of six
mice were used. During the study, two mice were removed due died before the final day of the
study. The weights of the mice are shown in Figure 48. It was found that the weights did not
significantly vary between the two groups. The visual inflammation can be observed in Figure 49.
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V2 and V6 were the only mice to show little visual signs of colonic inflammation and firm fecal
consistency. The results of the MPO assay conducted with the colon homogenates are shown in
Figure 50. It was observed that each group had a response consistent with high oxidative activity.
The colon V3 was an outlier within the study and the activity was much higher than the other
samples. Correlating the visual identification of inflammation, the response of the V6 colon was
low suggesting accuracy of the assay. No conclusions of the effectiveness of dexamethasone
were able to be drawn from the data of this study, suggesting that there remained a fundamental
issue with the assay that needed to be addressed before compounds could be screened for their
efficacy of reducing the induced colitis.

Figure 48 – Comparison weights of individual mice (left) and grouped (right) given vehicle and 5.0 mg/kg dexamethasone through
oral gavage.
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Figure 49 – Images of colons of mice give vehicle (top) and the mice provided with 5.0 mg/kg dexamethasone (bottom) through
oral gavage.
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MPO Assay Oral Dexamethasone

Figure 50 – Overlay of the MPO assay of the positive control (red) and negative control (black). The “soft” sample preparation
method was used for this study.

6.4.5 Corticosteroids as Positive Controls
Other corticosteroids were explored to compare to their efficacy with dexamethasone.
Prednisone was explored as an alternative corticosteroid for the reduction of colitis. Prednisone,
shown in Schematic 21 along with DNBS, has previously been explored by other groups and is an
FDA approved treatment for inflammation. The procedure that was used for these studies
followed the same modification of oral administration, lower installation volume for DNBS, and
soft wash for sample preparation to maintain any advantages that were observed in the previous
studies.
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Schematic 21 – Structure of the corticosteroids used within the studies.

Two groups of four mice were separated and housed during the study while treated with
prednisone. Prednisone was administered at 5 mg/kg daily by oral gavage. The formulation for
the preparation was 5:95 PG:HPMC. Mouse weights were monitored daily and summarized in
Figure 51. High variance of weight loss was observed within both groups. During necropsy, the
colons were photographed and shown in Figure 52. The percent weight loss correlated with the
degree of visual inflammation, suggesting inconsistency of the installation process with DNBS and
subsequent colon inflammation. The MPO assay was conducted using colons that underwent the
mechanical removal of feces before analysis. The results are shown Figure 53. Three distinct
groups were observed that included mice with no inflammation, mild inflammation, and severe
inflammation.
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Individual Mouse Percentages

Figure 51 – Weight comparison of indidual mice (right ) and the grouped weight change (left). Positive control mice were given a
5 mg/kg prednisone through oral gavage.

Figure 52 – Colons of vehicle mice (left) compared to mice treated with 5.0 mg/kg prednisone (right).
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MPO Assay Oral Prednisone

Figure 53 – MPO Assay overlay of the mice treated with prednisone (red) and vehicle (black). Multiple colon homogenatates did
not show any absorbance and were excluded from the measurement.

It was speculated that the DNBS model may be producing inconsistent forms of
inflammation within the CFW mice that may prevent the use of the small group size that was
used during these pilot studies. Alternatively, to the DNBS model, other colitis models have been
widely established for colitis such as the dextran sodium sulfate (DSS) model80. The general
structure of DSS is shown in Schematic 22. The molecule is a polymer that contains the sulfate
functionalities leading to a range of sizes in the initial reaction that generates the material.
Dextran sodium sulfate operates by disturbing the intercellular permeability causing for
permeation of intestinal bacteria into the intestinal lining and blood stream and recruitment of
neutrophils to the affected area. The size of the polymer is closely linked to the ability to
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permeate through membranes and produce the desired inflammatory effect. It has previously
been reported that the size range of 40-50 kDa is ideal for the modeling of IBD81.

Schematic 22 – Structure of the polymer of DSS size can range from 5 kDa to 60 kDa.

Unlike the DNBS model, the most common form of administration is the incorporation of
the compound into the water supply of the animal within the study for their consumption ad
libitum. This change to the procedure can cause a relationship between the behavior of the mice
to efficacy of the compound in longer studies. Due to its administration, DSS was expected to
induce a less localized form of inflammation in the large intestine. While this method has been
used by previous researchers, the use of CFW outbred mice had previously not been
demonstrated11, 82, 83. For this reason, the concentration of DSS that was used during the study
was initially based on the BALB/c model than adjusted to the observations within the CFW mice.
A group of two mice were provided with a water supply with 2.0% w/v DSS after the 7day accumulation period in the research facility. Both mice were given the vehicle through oral
gavage daily over the course of the study. The weights of the mice were collected and are
summarized in Figure 54. Both mice in the study saw a trend of weight loss each day during the
study on the same magnitude suggesting a similar effect. The MPO assay was conducted using
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the procedure described above and the results are shown in Figure 55. The small group size of
this study did not allow for strong conclusions to be drawn from the study, but it was found that
both mice developed colitis. A different degree of inflammation was observed for the MPO assay
results. However, the DSS model was able to induce a response and the group size could be
increased to further understand the oxidative activity in larger group sizes.

Figure 54 – Comparision of the wieghts of inidivual mice by weight lose (left) and weight over the study (left).

MPO Assay 2.0 % DSS

Figure 55 – MPO assay of the two mice treated with dextran sodium sulfate.
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A second group of mice, n = 4, were then treated with DSS for 10 days to determine if the
oxidative activity in the large intestine homogenates would unify towards the later days of the
study. The MPO assay results are shown in Figure 56. Similar to what was observed in previous
studies it was found that the weight loss over the study did not correlate well to the oxidative
activity in the MPO assay. Additionally, three of the mice were observed to have an elevated level
of oxidative activity while V4 had an extreme oxidative response. The conclusion of the study was
that the mice may be in different phases of the colitis model. Some of the mice were entering a
chronic response phase while others were still undergoing the acute response to the chemical
irritant. To address this issue the length of the study was returned to the 7-day period.

Figure 56 – Replicate of the DSS model10-day study n=4.

Furthermore, the concentration of DSS was increased from 2.0% w/v of the previous
studies to 3.0% w/v. The increase in the concentration was postulated to increase the colitis
within the mouse while remaining in the timeframe considered acute inflammation. The weight
loss of the group of mice in this study are shown in Figure 57. All mice during this study saw
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weight loss, although no mice crossed the previously determined threshold of 10% weight loss.
The MPO assay was then conducted on the colon homogenates collected and prepared at the
end of the 7-day study. The results of the MPO assay are shown in Figure 58. It was found that
the grouping of the oxidative response of all four colons within the study were closely grouped.
This would allow for a clear elevation of oxidative activity that could be reduced by the compound
provided in future studies.
The current procedure that can be used for the measurement of inflammatory response
are as follows. Mice colons are transferred to a biological hood for homogenization in PBS
solution on ice. Samples are transferred to test tubes and their masses are measured. Colons are
then homogenized after the addition of 1 mL of 50 mM phosphate buffer at pH 6.0 with a
detergent of 50 mM hexadecyltrimethylammonium bromide. The homogenates are then
transferred to centrifuge tubes and centrifuged at 10,000 RPM for 10 min. The BCA assay as
described above is then conducted along with a calibration curve to determine the protein
concentration of the homogenates. The protein concentration of an aliquot of each colon
homogenate is then diluted to 2000 µg/mL. 62 µL of 50 mM phosphate buffer at pH 6.0 is then
added to a series of wells in a clear 384 well plate. 8 µL of each sample is then transferred into a
corresponding will for a total of n = 4 replicates. A replicate series of wells is created on the plate.
10 µL of water is added to the new row creating a set of references for the background of each
sample. The active set has 10 µL 0.0024 % v/v hydrogen peroxide solution added to initiate the
assay. The plate is monitored in 30 s intervals for 15 min to create the traces of the oxidative
activity.
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Figure 57 – Weight lose of individual mice shown as a percentage of total starting mass (right) and indiviual mass (left).

Figure 58 – A compareson to the expected length of a mouse colon to the measure length of the mice within the study (left). The
MPO assay of the mice treated with 3.0% DSS and provided vehicle (right).

6.4.6 Other Measurements of Colitis Intensity
Initial measurement of the mice during these sets of studies hope to include measures of
coat quality, cage fecal consistency, and inflammation of the anus. Due to the incongruencies in
the initial weight loss and oxidative activity many of these measurements were excluded from
the initial study development to simplify the procedure to allow for the fast, and least resource
intensive development of this study using CFW mice. It was found that mice treated with 3.0%
w/v DSS ad libitum had a consistent response with the weight loss and oxidative activity of their
colons. The coat quality of the mice during the study seemed to poorly reflect upon the amount
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of inflammation observed in necropsy in all but the most severe cases of colitis. External rectal
inflammation was monitored in all the collected studies but found to have little significance to
the internal inflammation that would be attributed to colitis. For this reason, both the coat
quality and the external inflammation were used only to suggest a humane end point of the study
but not as a quantitative measure. Fecal consistency was a poor predicting factor towards colitis.
Mice in these studies were housed in groups of four, prevented the distinction of individuals
feces. It is suggested to maintain groups of four in housing to prevent the changes in social
behavior affecting dietary habits of the mice during the study. With this constraint, cage fecal
consistency would not be recommended for future studies.
The hematological and morphological analysis were removed from the analysis to allow
for the efficient optimization of the MPO assay during these studies, however, it would bolster
conclusions drawn on the colitis intensity and inflammatory response. Based on the initial
hematological data, it would be expected that mice that were experiencing colitis would have
elevated levels of granulocytes. The procedure of the hematological analysis is time sensitive
similar to the analysis done for the MPO Assay. A second researcher will need to perform this
analysis which is done off site to make sure that both measurements are collected within the
appropriate time frame. Morphological analysis will be interesting to measure the closer of crypts
within the intestinal lining. This measure is dependent upon the area that is sampled within the
colon but can add to the conclusion of severity of inflammation and mechanism of prevention.
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6.5

Future Studies on Inflammation
Future studies that will be conducted with the developed procedure for the measurement

of the colitis in mice will implement the developed method to screen compounds for efficacy on
the colitis model. Our goal is to gain an understanding about calcitroic acid and its efficacy in
preventing the inflammatory response. A study conducted with the positive control group of
dexamethasone will establish the new method showing the expected reduction of colitis. Once a
positive control compound has been found to reduce the level of inflammation within CFW mice,
this study will be used to screen both calcitroic acid and other compounds of interest of our group
for their efficacy. Compounds modeled after the structure of calcitroic acid that our group has
synthesized can in the future be screened using this method if a significant reduction in
inflammation is observed.

6.6

Conclusion
Inflammatory bowel disease affects a significant portion of the world population.

Treatments currently for this disease come with a wide range of side effects and some treatments
may not be optimal for every patient. Preliminary studies conducted by our group showed that
calcitroic acid was a part bile duct hepatic circulation possibly as a protecting agent against
inflammation induced by lithocholic acid. Our group set out to develop a method that would
show if calcitroic acid played a role as an anti-inflammatory agent within the intestinal tract. Our
study sought to use an outbred strand of mice that would model the human population more
accurately. The initial chemical irritant methods that were designed for DNBS were found to
induce too strong of an inflammatory response within the mice with a high degree of variance
between the mice. Some parameters such as the method of administration were changed from
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the initial procedure such as the use of IP administration to prevent injuries of the intestine. The
final method that was developed was a 7-day study in which mice are provided ad libitum 3.0%
DSS w/v in their water supply. It was observed based on the visual inflammation, weight loss as
well as the oxidative activity of colon homogenate that the DSS treated mice had symptoms of
inflammation. While the efficacy of calcitroic acid still needs to be determined, the assay that has
been designed has a close variance between the vehicle mice allowing for the reduction of
inflammation to accurately be determined in future studies.
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